documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item c cybersecurity item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences kite ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey sovaldi stribild sunlenca tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig trademarks trade names property respective owners certain amounts percentages annual report may sum recalculate due roundingthis annual report including part item risk factors part ii item managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities exchange act amended words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs plans expectations respect products product candidates corporate strategy business operations financial projections use capital expectations regarding impairment charges related phase evoke study collaboration licensing arrangements patent protection estimated loss exclusivity products product candidates ongoing litigation investigation matters statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item risk factors annual report given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof unless otherwise specified except required federal securities laws rules regulations us securities exchange commission undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise evaluating business carefully consider risks described part item risk factors annual report risks contained herein could materially adversely affect business results operations financial condition part item business gilead sciences inc including consolidated subsidiaries referred gilead company us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis coronavirus disease covid cancer operate countries worldwide headquarters foster city california business products transformed care people around world discovering developing delivering innovative medicines address unmet medical needs virology oncology therapeutic areas innovative medicines represent advancements offering firstinclass therapies greater efficacy enhanced modes delivery convenient treatment prevention regimens improved resistance profiles reduced side effects primary revenuegenerating products approved indications us follows hiv biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy singletablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine ftc tenofovir alafenamide taf genvoya oral formulation dosed day treatment hiv infection certain patients genvoya singletablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat ftc taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications ftc taf descovy also approved us food drug administration fda pre exposure prophylaxis prep indication reduce risk sexually acquired hiv infection certain atrisk patients odefsey oral formulation dosed day treatment hiv infection certain patients odefsey singletablet regimen fixeddose combination antiretroviral medications ftc taf rilpivirine marketed janssen sciences ireland unlimited company one janssen pharmaceutical companies johnson johnson janssen compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed us complera europe eviplera singletablet regimen fixeddose combination antiretroviral medications tenofovir disoproxil fumarate tdf ftc janssens rilpivirine hydrochloride truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients truvada fixeddose combination antiretroviral medications tdf ftc truvada also approved fda prep indication reduce risk sexually acquired hiv infection certain atrisk patients stribild oral formulation dosed day treatment hiv infection certain patients stribild singletablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tdf ftc sunlenca hiv capsid inhibitor tablet form oral use injection subcutaneous use sunlenca combination antiretrovirals indicated twiceyearly treatment hiv infection heavily treatmentexperienced adults multidrug resistant hiv infection failing current antiretroviral regimen due resistance intolerance safety considerations covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicated treatment covid certain adults pediatric patients days age older weighing least kg hospitalized ii hospitalized mildtomoderate covid high risk progression severe covid including hospitalization death viral hepatitis epclusa oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adults pediatric patients years age older genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin addition authorized generic version epclusa distributed separate subsidiary asegua therapeutics llc vemlidy oral formulation taf dosed day treatment chronic hepatitis b virus hbv infection adults pediatric patients years age older compensated liver disease harvoni oral formulation oncedaily singletablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults pediatric patients years age older genotype without cirrhosis compensated cirrhosis ii genotype decompensated cirrhosis combination ribavirin iii genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin addition authorized generic version harvoni distributed separate subsidiary asegua therapeutics llc viread oral formulation tdf dosed day treatment chronic hbv infection adults pediatric patients years age older weighing least kg oncology yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car tcell therapy treatment adult patients large bcell lymphoma lbcl refractory firstline chemoimmunotherapy relapses within months firstline chemoimmunotherapy ii relapsed refractory lbcl two lines systemic therapy including diffuse lbcl dlbcl otherwise specified primary mediastinal lbcl highgrade bcell lymphoma dlbcl arising follicular lymphoma fl iii relapsed refractory fl two lines systemic therapy trodelvy sacituzumab govitecanhziy injection intravenous use trop directed antibody topoisomerase inhibitor conjugate indicated treatment adult patients unresectable locally advanced metastatic triplenegative breast cancer tnbc received two prior systemic therapies least one metastatic disease ii unresectable locally advanced metastatic hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting iii locally advanced metastatic urothelial cancer uc previously received platinumcontaining chemotherapy either programmed death receptor pd programmed deathligand pdl inhibitor tecartus brexucabtagene autoleucel suspension intravenous infusion car tcell therapy treatment adult patients relapsed refractory mantle cell lymphoma mcl ii relapsed refractory bcell precursor acute lymphoblastic leukemia indication approved accelerated approval fda continued approval indication may contingent upon verification description clinical benefit confirmatory trials ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability disaggregated revenue amounts contributed products listed well total product sales include approved products see note revenues notes consolidated financial statements included part ii item annual report revenue share revenues also generate revenues activities including revenue share combination products royalties outbound licenses intellectual property payments received collaborations thirdparty partners example pursuant collaboration janssen receive revenue share cobicistat ftc taf components symtuza darunavircobicistatftctaf fixeddose combination product commercialized janssen include revenue share symtuza product sales description collaborations janssen partners see note collaborations arrangements notes consolidated financial statements included part ii item annual report commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products us exclusively wholesale channel year ended december approximately product sales us approximately total worldwide revenues three large wholesalers cencora inc formerly known amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute products europe countries outside us product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing also face significant competition third parties pursue development products technologies may competitive existing products research programs third parties include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs addition products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected research development research development rd mission discover develop transformational therapies areas high unmet medical need product development efforts focused primarily viral diseases oncology inflammatory diseases team research scientists engaged discovery development new molecules technologies hope lead approval innovative medicines therapies transform care people around world committed significant resources internal rd opportunities external business development activity drive innovation growth business development product candidates investigational therapies pipeline subject various risks uncertainties could result delays prevent completion development approval product candidates information risks uncertainties see item risk factors face risks clinical trials including potential unfavorable results delays anticipated timelines disruption drug development inherently risky many product candidates investigational therapies fail development process continued invest advance rd pipeline across therapeutic areas summary product candidates phase clinical trials pending marketing authorization review fda european medicines agency ema product candidates viral diseases product candidates description regulatory filings bulevirtide biologics license application filed fda bulevirtide treatment chronic hepatitis delta virus hdv infection granted orphan drug breakthrough therapy designations fda indication approval pending resolution certain manufacturing delivery concerns cited complete response letter issued fda october phase lenacapavir lenacapavir evaluated hiv prep indication product candidates oncology product candidates description phase axicabtagene ciloleucel axicabtagene ciloleucel car tcell therapy evaluated secondline later treatment highrisk fl ii firstline treatment high risk lbcl sacituzumab govitecanhziy breast cancer sacituzumab govitecanhziy evaluated firstline treatment pdl negative metastatic tnbc ii hrher chemonaive metastatic breast cancer collaboration merck sharpe dohme llc merck also evaluated combination mercks pembrolizumab firstline treatment pdl positive metastatic tnbc ii adjuvant treatment early tnbc lung thoracic cancer sacituzumab govitecanhziy evaluated second thirdline treatment non small cell lung cancer nsclc also evaluated combination mercks pembrolizumab firstline treatment pdl positive nsclc genitourinary cancer sacituzumab govitecanhziy evaluated secondline treatment metastatic uc fda granted accelerated approval trodelvy secondline metastatic uc april domvanalimab zimberelimab collaboration arcus biosciences inc arcus combination zimberelimab antipd monoclonal antibody domvanalimab fcsilent antitigit antibody chemotherapy evaluated firstline treatment nsclc ii firstline treatment upper gastrointestinal tract cancer collaboration arcus combination zimberelimab domvanalimab evaluated firstline treatment nsclc january announced discontinuation enrollment study additional information regarding collaborations merck arcus see note collaborations arrangements notes consolidated financial statements included part ii item annual report also received regulatory approvals authorizations fda european commission ec new products expanded indications products including product regulatory approval authorization veklury fda ec approved expanded use veklury treat covid appropriate patients mild severe hepatic impairment well people severe renal impairment including dialysis hepcludex ec granted full marketing authorization hepcludex treatment adults hdv compensated liver disease hepcludex initially granted conditional marketing authorization july bulevirtide remains approved treatment hdv european union eu approved us yescarta fda approved label update yescarta include overall survival data phase zuma study showed statistically significant overall survival improvement yescarta secondline relapsed refractory lbcl versus standard care trodelvy fda approved trodelvy treatment unresectable locally advanced metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting ec approved trodelvy monotherapy treatment adult patients unresectable metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies advanced setting addition seek enhance commercial portfolio clinical pipeline across multiple therapeutic areas strategic collaborations inlicensing acquisitions entered multiple strategic transactions spanning work virology oncology inflammation including entered new strategic collaborations including assembly biosciences inc advance research development novel antiviral therapies including herpesviruses hbv hdv ii tentarix biotherapeutics inc tentarix discover develop novel therapies across oncology inflammation using tentarixs proprietary tentacles platform iii arcellx inc arcellx codevelop cocommercialize arcellxs cartddbcma treatment relapsed refractory multiple myeloma expanded existing collaborations arcellx exercise option arcsparx aclx program multiple myeloma expand scope existing anitocel collaboration include lymphomas make additional equity investment million ii arcus include research programs inflammatory diseases iii nurix therapeutics inc exercise option license investigational targeted protein degrader molecule nx potential applications treatment rheumatoid arthritis inflammatory diseases entered exclusive license agreement compugen ltd laterstage development commercialization novel preclinical antiil binding protein antibodies including com potential treat various tumor types completed acquisitions xinthera inc add additional early pipeline assets oncology inflammation including rights portfolio small molecule inhibitors targeting parp oncology well mk inflammatory diseases ii tmunity therapeutics inc add nextgeneration car tcell therapies technologies including armored car technology platform potential enhance antitumor activity rapid manufacturing processes strategic business development activity reflects commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted us eu primary typically compound patents key product candidates described product candidates fixeddose combinations singletablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients singletablet regimen key product candidates patent expiration us eu viral diseases lenacapavir bulevirtide oncology axicabtagene ciloleucel sacituzumab govitecanhziy zimberelimab domvanalimab listed expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted composition matter patent expired eu eu us patent applications pending relating proprietary manufacturing processes regulatory exclusivity us expires collaboration arcus dates parentheses reflect estimated expiration date patents may issued currently pending applications following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted us eu primary typically compound patents principal products products fixeddose combinations singletablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients singletablet regimen products patent expiration us eu descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy hepcludex sunlenca listed expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted applicable settlement license agreements generic manufacturers relating patents protect principal products noted nature timing loss exclusivity products depends multitude factors loss exclusivity may earlier certain circumstances information see item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties september gilead five generic manufacturers lupin ltd apotex inc macleods pharma ltd hetero labs ltd cipla ltd reached agreements settle us patent litigation concerning patents protect taf descovy vemlidy odefsey products composition matter patent expired eu eu us patent applications pending relating proprietary manufacturing processes gilead mylan pharmaceuticals reached agreement settle patent litigation concerning patents protect cobicistat stribild genvoya products january fda granted pediatric exclusivity veklury extends nonexpired exclusivities six months reflected presently reported date regulatory exclusivity us expires patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api products held third parties acquired exclusive rights patents agreements parties may obtain patents certain products many years marketing approval obtained result commercial value patent may limited patent term based date patent application filed may prior regulatory approval commercial sale related product however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputation may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use products research activities patent applications confidential period time filing may know competitors filed applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection filing patent applications factintensive complex process may file patent applications ultimately result patents patents provide adequate protection related product future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries may face criticism result legitimate use patent systems protect investments new useful innovations medicine incentives exclusivities relating products product candidates may change future aware several countries considering changes support sharing make use new inventions could impact current patent systems protections innovation changes could also impact voluntary licensing patent programs establish products support access medicines description significant pending legal proceedings see note commitments contingencies notes consolidated financial statements included part ii item annual report see also item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partners cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites cell therapy products established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities manufacture distribute certain products api clinical andor commercial uses end facilities include foster city california conduct process chemistry research analytical method development formulation device development activities manufacture api drug product clinical trials la verne california manufacture ambisome also package label majority commercial products distribution americas pacific rim also utilize la verne facility clinical manufacturing sterile drug products oceanside california utilize facility commercial retroviral vector manufacturing clinical manufacturing process development biologics candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy products santa monica california utilize facility clinical manufacturing processing cell therapy products frederick maryland utilize facility clinical commercial manufacturing processing cell therapy products cork dublin ireland utilize cork facility commercial manufacturing packaging labeling products also perform quality control testing labeling packaging final release many products cork facility distributed eu international markets facility dublin edmonton canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes hoofddorp netherlands utilize facility commercial manufacturing processing cell therapy products thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions information thirdparty manufacturers see item risk factors may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities observe complying regulations thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies cell therapy products required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues human capital gileads success depends work dedicated employees embrace shared sense purpose culture excellence human capital objective make gilead employer choice best talent industry gileads key priorities human capital management include inclusion diversity health safety total rewards employee development engagement compensation talent committee board directors oversees overall human capital management inclusion diversity inclusion gilead core value believe building inclusive diverse workforce critical enabling gileads mission global inclusion diversity council responsible governance matters tracking progress goals promoting culture inclusion global inclusion diversity council chaired chairman chief executive officer ceo includes members leadership team gilead equal opportunity employer committed inclusive practices creating internal external pipelines diverse talent well building awareness capabilities accountability among people managers gilead implemented multiple programs train managers inclusion diversity topics created strategies initiatives focused attracting developing retaining diverse talent driving inclusive culture workplace organizational leaders required regularly review since addition employee resource groups ergs support diverse employees aim raise awareness different cultures within workplace cultivate diversity business strength support gileads talent acquisition strategy promote equal opportunities source attract recruit diverse candidates executive sponsors leaders ergs contribute advancement inclusion diversity commitments annual planning collaborative efforts support communities inside outside gilead believe gileads inclusive diverse workforce foundation innovation productivity gileads commitment equal employment opportunity furthers efforts cultivate celebrate equitable culture belonging december gilead approximately employees gileads global workforce approximately female additionally women represented gileads leadership defined vice president level us based employees voluntary selfidentification workforce white asian hispanic black health safety productivity gilead committed providing workplace employees promotes health wellbeing safety productivity provide competitive benefits package support health wellbeing employees see total rewards workplace safety training security program together various compliance protocols designed support safety employees routinely train educate employees workplace safety security promote employee productivity continue address employees needs providing meaningful benefits flexible approach work arrangements believe flexible work program positions us competitive talent support employee safety wellbeing also creating collaborative environment connections fuel innovation response employee feedback also implemented multiple enterprise initiatives address areas opportunity improve efficiency remove barriers speed execution total rewards gileads total rewards portfolio designed optimize employees performance support wellbeing allowing focus missioncritical work year reassess total rewards package confirm whether offers benefits incentives align total rewards philosophy portfolio varies country subject employee eligibility requirements includes limited competitive base salary paid family leave incentive compensation family support services stock awards family planning assistance eg fertility adoption surrogacy employee stock purchase plan health care navigation lgbtq community k savings plan company match vests immediately cancer support services health wellbeing benefits student loan repayment tuition assistance flexible work arrangements employee assistance programs flexible spending accounts digital wellbeing platform paid time global wellbeing reimbursement payforperformance company committed addressing pay equity employee salaries informed market research marketbased ranges assessed annually performance reviews policy compensation decisions made without regard personal characteristics gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status also conduct annual pay equity review employee compensation effort strive make pay practices gender raceneutral employee development engagement employee development engagement maximizes potential performance member workforce critical achieving business goals gilead offers number internal external professional management leadership development training programs help employees develop technical crossfunctional leadership skills tools grow careers started multiyear approach support development people leaders gilead recognizing complexity challenges roles supporting impact growth development employees approximately people leaders started development journey additional planned addition internal development employees receive reimbursement tuition expenses incurred pursuing undergraduate graduate certificate courses accredited college university strive employer choice industry listening strategy gathers input employees shape engagement strategies programs measure progress addition ongoing internal external data collection benchmarking conducted comprehensive reviews employee experience including use employee surveys results surveys play key role determining direction culture well companys broader response emerging developments corporate responsibility investing corporate responsibility core business strategy reflects values accountability inclusion teamwork excellence integrity service mission advance global health providing innovative therapeutics areas unmet need way socially responsible environmentally sustainable gileads corporate responsibility programs reflect commitment stakeholders environmental social governance esg strategy performance overseen nominating corporate governance committee board directors managed corporate responsibility committee comprised leaders key departments across company corporate responsibility committee responsible reviewing esg issues appropriate integrating overall business strategy operations additional information program esg highlights available gileads esg impact report gileads website httpswwwgileadcommediafilespdfsyirpdfsenvironmentalsocialgovernance impactreportpdf esg goals aspirational may change statements regarding goals related initiatives guarantees promises met seasonality operations worldwide product sales reflect significant degree seasonality enduser demand however us fluctuations wholesaler inventory levels impact product sales recent years observed strong wholesaler subwholesaler purchases products second half year resulting inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds adverse changes economic conditions increased competition buying patterns also could impact product sales recorded particular quarter information see item risk factors face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories government regulation operations activities subject extensive regulation numerous government authorities us eu countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming significant impact capital expenditures results operations regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda us ema ec eu well national authorities eu member states must approve drug sold respective country countries general process drug approval us summarized many countries including countries eu eu centralized procedure similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering risk indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating preventing disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective appropriate safety profile phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application biologics license application supplemental application fda seeking approval sell drug candidate particular use fdas discretion fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees drug met required level safety efficacy particular use approve application allow us sell drug us use unusual however fda decline approve application believes drug candidate safe enough efficacious enough ie appropriate benefitrisk profile believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit manufacturing issues certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit even approving drug fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards concerns safety efficacy uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold us facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland netherlands also must obtain local licenses permits compliance local regulatory requirements fda may employ one several tools facilitate expedite development review drug including fast track designation breakthrough therapy designation accelerated approval designation priority review designation fast track designation designed facilitate development review drug treats serious condition fills unmet medical need breakthrough therapy designation designed expedite development review drug treats serious condition preliminary clinical evidence demonstrates substantial improvement available therapies accelerated approval drug may granted fda drug treats serious condition fills unmet medical need studied safety efficacy priority review designation means fdas goal take action application within six months filing fda may grant priority review designation drug would provide significant improvement safety effectiveness treatment diagnosis prevention serious condition eu regulatory system approval process eu products subject variety eu eu member state regulations governing clinical trials commercial sales distribution required obtain marketing authorization eu market medicinal products relevant market conduct clinical trials eu governed among others directive ec directive ec ich good clinical practice guidelines impose legal regulatory obligations similar provided applicable us laws conduct clinical trials eu must approved competent authorities eu member states clinical trials take place positive opinion must obtained relevant ethics committee relevant member state eu legislator adopted regulation eu replace directive ec introduce coordinated procedure authorization clinical trials regulation entered application january marketing authorization holders manufacturers importers wholesalers distributors medicinal products placed market eu required comply number regulatory requirements including pharmacovigilance gmp compliance requirement obtain manufacturing import andor distribution licenses issued competent authorities eu member states failure comply requirements may lead imposition civil criminal administrative sanctions including suspension marketing manufacturing authorizations pricing reimbursement successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement us eu significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices including rebates may required pay medicaid agencies discounts may required pay covered entities section b public health service act b result price increases implement time time certain products may limited effect net product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement pressures government agencies third parties required rebates discounts pricing pressures face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories health care fraud abuse laws antibribery laws subject various us federal state laws pertaining health care fraud abuse including antikickback laws false claim laws anti kickback laws make illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimbursed federal healthcare program including purchase prescription particular drug false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim addition fda regulates written verbal communications products addition federal law states also consumer protection false claims laws due breadth statutory provisions attention given law enforcement authorities sales marketing patient support medical clinical public affairs activities may subject scrutiny laws example recently enhanced scrutiny government enforcement authorities companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance reimbursement support offerings clinical education programs promotional speaker programs similarly europe interactions pharmaceutical companies physicians subject strict laws regulations industry selfregulation codes conduct physicians codes professional conduct applicable including eu member states anticorruption laws uk bribery act addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us unlawful acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program even disagree governments perspective violated rules guidance similar violations competitors could also negatively impact reputation industry increase governmental public scrutiny business products information see item risk factors impacted evolving laws regulations legislative regulatory actions applicable healthcare industry environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements securities exchange act exchange act therefore file periodic reports proxy information statements information us securities exchange commission sec sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec website wwwgileadcom link investors website financials sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act website references provided throughout document convenience content referenced websites constitute part incorporated reference annual report executive officers directors following tables list executive officers directors filing date annual report executive officers name age position daniel p oday chairman chief executive officer andrew dickinson chief financial officer johanna mercier chief commercial officer merdad v parsey md phd chief medical officer deborah h telman executive vice president corporate affairs general counsel directors name age principal occupation employment daniel p oday chairman chairman chief executive officer gilead sciences inc kevin e lofton lead independent director retired chief executive officer common spirit health jacqueline k barton phd professor emerita california institute technology jeffrey bluestone phd president chief executive officer sonoma biotherapeutics inc professor emeritus university california san francisco sandra j horning md retired chief medical officer roche inc kelly kramer retired chief financial officer cisco systems inc ted w love md chair board directors biotechnology innovation organization harish manwani senior operating partner blackstone inc retired chief operating officer unilever group javier j rodriguez chief executive officer davita inc anthony welters chairman chief executive officer cinq care inc retired senior advisor office ceo unitedhealth group item risk factors evaluating business carefully consider following discussion material risks events uncertainties make investment us speculative risky addition information annual report manifestation following risks uncertainties could circumstances may may able accurately predict materially adversely affect business operations growth reputation including commercial scientific reputation products prospects product pipeline sales operating financial results financial condition cash flows liquidity stock price note factors investors permitted private securities litigation reform act possible predict identify factors operations could also affected factors events uncertainties presently known us currently consider present significant risks operations therefore consider following risks complete statement potential risks uncertainties face product commercialization risks certain products subject us additional heightened risks hiv receive substantial portion revenue sales products treatment prevention hiv infection year ended december sales hiv products accounted approximately total product sales may unable sustain increase sales hiv products number reasons including market share gains competitive products including generics inability introduce new hiv medications necessary remain competitive case may need scale back operations including future drug development spending research development rd efforts example many hiv products contain tenofovir alafenamide taf belongs nucleoside class antiviral therapeutics changes treatment prevention paradigm hiv nucleosidebased therapeutics remain preferred regimen hiv product sales would adversely impacted veklury face risks related supply sale veklury approved us food drug administration fda treatment patients coronavirus disease covid veklury sales generally reflect covid related rates severity infections hospitalizations well availability uptake effectiveness vaccines alternative treatments covid may world health organization declared end covid public health emergency international concern future sales veklury short longterm remain uncertain accurately forecast demand manufacture veklury levels align actual demand may experience product shortages build excess inventory may need written cell therapy advancing novel personalized therapy yescarta tecartus chimeric antigen receptor car tcell therapies creates significant challenges including educating certifying medical personnel regarding procedures potential side effects cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy program required fda securing sufficient supply medications manage side effects tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impacts efficacy cell therapy developing maintaining robust reliable process engineering patients cells facilities infusing back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community fda approved cell therapies including yescarta tecartus must continue demonstrate medical community potential advantages cell therapy compared existing future therapeutics november fda announced investigating risk tcell malignancies patients received treatment car tcell therapy noting overall benefits car tcell therapy products continue outweigh potential risks approved uses january fda determined safety labeling issues needed approved car tcell therapies including boxed warning possible risk tcell malignancies patients treated car tcell therapy additionally fda requested continued monitoring reporting cases secondary cancers challenges related reimbursement yescarta tecartus see also existing products subject reimbursement pressures government agencies third parties required rebates discounts pricing pressures rely thirdparty sites collect patients white blood cells known apheresis centers well shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta tecartus patients vendors may encounter disruptions difficulties could result product loss regulatory action apheresis centers may also choose participate quality certification process may unable complete certification timely manner could delay constrain manufacturing commercialization efforts also face risks related inhouse car tcell therapy manufacturing facilities california maryland netherlands spanning process development vector manufacturing clinical trial production commercial product manufacturing quality reliability speed critical cell therapy manufacturing quickly safely deliver cell therapies patients delays quality issues manufacturing operations could adversely affect business damage reputation addition may able sufficiently increase manufacturing network capacity meet growing demand success depends developing commercializing new products expanding indications existing products unable launch commercially successful new products new indications existing products business adversely impacted launch commercially successful products necessary grow business cover substantial rd expenses offset revenue losses existing products lose market share due factors competition loss patent exclusivity many difficulties uncertainties inherent drug development introduction new products product development cycle characterized significant investments resources long lead times unpredictable outcomes due nature developing medicines human use expend significant time resources product pipeline without assurance recoup investments efforts commercially successful high rate failure inherent discovery development new products failure occur point process including late process substantial investment face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories may unable accurately predict demand products including uptake new products demand depends number factors example product demand may adversely affected physicians see benefit products additionally nonretail sector us includes government institutions including state aids drug assistance programs us department veterans affairs correctional facilities large health maintenance organizations tends less consistent terms buying patterns often causes quarteroverquarter fluctuations mirror actual patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products expect continue experience fluctuations purchasing patterns nonretail customers light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels may continue see trend future sell distribute products us exclusively wholesale channel year ended december approximately product sales us three wholesalers cencora inc formerly known amerisourcebergen corporation cardinal health inc mckesson corporation us wholesalers entered inventory management agreements make estimates determine enduser demand may accurate matching inventory levels actual enduser demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match enduser demand addition inventory held retail pharmacies non wholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even enduser demand changed addition observed strong wholesaler subwholesaler purchases products second half year typically results inventory drawdown wholesalers subwholesalers subsequent first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers new branded generic products entering major markets affects ability maintain pricing market share products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing number companies pursuing development products technologies may competitive existing products research programs competing companies include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs may adversely impacted competitors gain market share result new technologies commercialization strategies otherwise existing products subject reimbursement pressures government agencies third parties required rebates discounts pricing pressures product reimbursements successful commercialization products depends part availability amount thirdparty payer reimbursement products related treatments medical services markets sell products products mature pricing pressures private insurers government payers often result reduction net product prices legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently example september fda issued final rule implementing pathway importation certain prescription drugs canada january fda authorized floridas proposed program import prescription drugs canada although florida must meet certain additional requirements begin shipments prescription drugs us canada list specific prescription drugs florida intends import made public may adversely impacted legislative regulatory actions though difficult predict impact use reimbursement products product pricing discounts rebates us european union eu significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services volume drug pricingrelated legislation dramatically increased recent years including us congress enacted laws requiring manufacturer refunds certain amounts discarded drug singleuse vials eliminating existing cap medicaid rebate amounts beginning us congress enacted inflation reduction act act among changes requires department health human services negotiate medicare prices certain drugs starting drugs adding drugs adding drugs subsequent years imposes inflationbased rebate medicare part b utilization starting part utilization beginning october restructures medicare part benefit cap outofpocket expenses part beneficiaries beginning effective january increases part plans contributions catastrophic coverage phase increases manufacturers discount contributions across coverage phases manufacturers must pay discount initial coverage phase discount catastrophic phase drugs utilized part beneficiaries including low income subsidy patients continue evaluate potential impact act business centers medicare medicaid services cms issued number guidance documents remains unclear certain provisions implemented additional guidance legislation rulemaking may issued could reflect governments evolving views addition multiple manufacturers trade organizations challenged medicare negotiation provisions act additional legal challenges may filed future full impact act business pharmaceutical industry remains uncertain time anticipate act increase payment obligations redesigned part discount program limit prices charge products increase rebates must provide government programs products thereby reducing profitability negatively impacting financial results many state legislatures considering already passed law legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring manufacturers publicly report proprietary pricing information creating review boards prices establishing drug payment limits encouraging use generic drugs example august colorado prescription drug affordability review board selected genvoya affordability review possible board may designate upper limit amount certain purchasers payors pay genvoya initiatives legislation may cause added pricing pressures products resulting impact business uncertain time many countries outside us including eu member states established complex lengthy procedures obtain price approvals coverage reimbursement periodically review pricing reimbursement decisions outcome reviews predicted could adverse effect pricing reimbursement medical products eu member states reductions pricing medical products one member state could affect price member states negative impact financial results substantial portion product sales subject significant discounts list price including rebates may required pay state medicaid agencies discounts provided covered entities section b public health service act b changes b program medicaid program federal state level could material adverse effect business example continued growth b program limits prices may charge increasing percentage sales changes calculation rebates medicaid program could substantially increase medicaid rebate obligations decrease prices charge bcovered entities march implemented contract pharmacy integrity initiative branded hepatitis c virus hcv products integrity initiative involve products asegua therapeutics llc integrity initiative requires covered entities enter b bill toship arrangements contract pharmacies branded hcv products provide claims level data units dispensed contract pharmacies covered entities without inhouse pharmacy choose participate initiative designate single contract pharmacy shipment certain manufacturers implemented contract pharmacy integrity programs received enforcement letters us department health human services hhs asserting programs violate b statute referred hhs office inspector general assessment civil monetary penalties subject administrative dispute resolution proceedings brought behalf covered entities manufacturers currently challenging hhs position ongoing litigation certain states also enacted laws requiring manufacturers provide b pricing contract pharmacy arrangements believe laws challenged ongoing litigation invalid also believe integrity initiative complies requirements b statute however additional legal legislative developments respect b program including potential litigation hhs stakeholders may negatively impact ability implement continue integrity initiative addition standard reimbursement structures may adequately reimburse innovative therapies example beginning fiscal year cms established new severityadjusted diagnosisrelated group drg medicare inpatient reimbursement car tcell products yescarta tecartus new drg significantly higher base payment amount prior drg payment available may sufficient reimburse hospitals cost care patients receiving yescarta tecartus reimbursement aligned well account treatment costs medicare beneficiaries may denied access misalignment could impact willingness hospitals offer therapy doctors recommend therapy additionally eu barriers reimbursement individual countries could limit uptake yescarta tecartus moreover estimate rebates required pay connection sales particular quarter based claims data prior quarters us actual rebate claims typically made payers one three quarters arrears actual claims payments may vary significantly estimates may experience adverse impacts resulting importation products lower price markets distribution illegally diverted counterfeit versions products prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported resold countries lower price markets us sales could also affected fda permits importation drugs canada entered agreements generic drug manufacturers well licensing agreements medicines patent pool united nationsbacked public health organization allow generic drug manufacturers manufacture generic versions certain products distribution certain low middleincome countries may adversely affected generic versions products whether produced andor distributed agreements exported us eu markets higher prices eu required permit products purchased one eu member state sold another member state purchases products member states selling prices relatively low resale member states selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter additionally diverted products may used countries approved patients may source diverted products outside legitimate supply chain diverted products may handled shipped stored inappropriately may affect quality andor efficacy products could harm patients adversely impact us also aware existence various suppliers around world without gileads authorization purport source products generic versions products sell use countries products approved result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances could harm patients adversely impact us third parties illegally distributed sold may continue illegally distribute sell illegally diverted counterfeit versions medicines meet rigorous quality standards manufacturing supply chain example part us civil enforcement lawsuit coordination law enforcement pursuant court order seized thousands bottles gileadlabeled medication counterfeit supply chain documentation investigation revealed pharmaceutical distributors authorized gilead sell gilead medicine sold purportedly genuine gilead medicine sourced illegal counterfeiting scheme independent pharmacies nationwide illegally diverted counterfeit versions gileadbranded medicines exist may pose serious risk patient health safety actions stop prevent distribution sale illegally diverted counterfeit versions medicines around world may costly unsuccessful may adversely affect patients reputation business including product revenues financial results product development supply chain risks face risks clinical trials including potential unfavorable results delays anticipated timelines disruption required demonstrate safety efficacy product candidates develop intended use extensive preclinical studies clinical trials results studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products face numerous risks uncertainties clinical trials could result delays prevent completion development approval product candidates including challenges clinical trial protocol design ability enroll patients clinical trials possibility unfavorable inadequate trial results support development product candidates including failure meet trials primary endpoint safety issues arising clinical trials need modify delay clinical trials perform additional trials example october announced fda issued complete response letter biologics license application bulevirtide treatment adults hepatitis delta virus infection january announced phase evoke study evaluating sacituzumab govitecanhziy meet primary endpoint overall survival previously treated metastatic nonsmall cell lung cancer nsclc believe represents indicator potential impairment first quarter could result us required record impairment charge three months ended march impairment charge unable reasonably estimate time could material impact results operations information see item managements discussion analysis financial condition results operations results operations inprocess research development impairments addition february announced full clinical hold placed fda magrolimab studies myelodysplastic syndromes acute myeloid leukemia pursue development magrolimab hematologic cancers result may unable successfully complete clinical trials anticipated timelines based trial results possible fda regulatory authorities approve product candidates market approvals include significant limitations products use addition clinical trials involving commercial products raise new safety issues existing products could adversely impact business past may future make strategic decision discontinue development product candidates including limited situations believe commercialization difficult relative opportunities pipeline example february announced full clinical hold placed fda magrolimab studies myelodysplastic syndromes acute myeloid leukemia based results data clinical studies pursue development magrolimab hematologic cancers addition january announced partner arcus biosciences inc arcus discontinuation enrollment phase arc study evaluating domvanalimab plus zimberelimab firstline locally advanced metastatic pdlhigh nsclc based strategic prioritization advance potentially accelerate phase studies collaboration arcus therefore product candidates may never successfully commercialized may unable recoup significant rd clinical trial expenses incurred expect spend significant time resources clinical trial activities without assurance recoup investments efforts commercially successful also risks associated use third parties clinical trial activities extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals may adversely affected may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners products manufactured facilities thirdparty manufacturers corporate partners result complex highly regulated manufacturing processes depend thirdparty manufacturers corporate partners perform manufacturing activities effectively timely basis majority active pharmaceutical ingredients drug products third parties independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema well comparable regulations jurisdictions manufacturing operations also subject routine inspections regulatory agencies adverse developments affecting resulting manufacturing operations operations thirdparty manufacturers corporate partners may result shipment delays inventory shortages lot failures product withdrawals recalls interruptions commercial supply products incurred continue incur inventory writeoff charges expenses products fail meet specifications quality standards well changes may adopt manufacturing strategy may need undertake costly remediation efforts seek costly manufacturing alternatives example see note financial information notes consolidated financial statements included part ii item annual report discussion certain charges incurred related changes manufacturing strategy developments could increase manufacturing costs cause us lose revenues market share damage reputation addition manufacturing issues may cause delays clinical trials applications regulatory approval example unable remedy deficiencies cited fda regulatory agencies inspections existing products timing regulatory approval product candidates development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries business may adversely affected approval product candidates delayed production products interrupted may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials manufacture sell products unable purchase enough materials find suitable alternative materials timely manner development efforts product candidates may delayed ability manufacture sell products could limited example us shortage certain cancer drugs backbone standardof care treatments carboplatin cisplatin also used rd clinical trials observed minimal impacts oncology clinical trials date shortages continue increase magnitude ongoing future oncology clinical trials may delayed halted adversely impacted suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control maintain full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand addition deliveries materials suppliers interrupted reason including result natural disasters extreme weather conditions may unable ship certain products commercial supply supply product candidates development clinical trials also products materials utilize operations manufactured one supplier one facility may able replace timely manner commercially reasonable terms problems single suppliers facilities depend including event disaster earthquake flood fire equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside us result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside us supplying materials could adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability conduct clinical trials product candidates manufacture sell products could impaired regulatory legal risks operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries filed anticipate continue file marketing approval additional countries additional indications products future marketing applications file may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use state certainty whether product candidates development approved launched whether able develop license acquire additional product candidates products whether products launched commercially successful manufacture sell products subject extensive regulation review example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk certain circumstances may required implement risk evaluation mitigation strategy program products could include medication guide patient package insert communication plan healthcare providers restrictions distribution use product elements fda deems necessary assure safe use drug discovery previously unknown problems marketed products product candidates including serious safety resistance drug interaction issues problems manufacturing safety reporting promotional activities may result regulatory approvals delayed denied granted significant restrictions products including limitations withdrawal products market failure comply requirements imposed fda could result significant civil monetary penalties fines suspensions regulatory approvals product recalls seizure products criminal prosecutions impacted evolving laws regulations legislative regulatory actions applicable healthcare industry healthcare industry subject various federal state international laws regulations pertaining drug approval reimbursement rebates price reporting healthcare fraud abuse data privacy security us laws include antikickback false claims laws federal food drug cosmetic act laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute b statute laws regulate written verbal communications products individual state laws relating pricing sales marketing practices health insurance portability accountability act federal state laws relating privacy security health information actual alleged violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state healthcare programs including medicare medicaid us department veterans affairs us department defense health programs actions executives overseeing business significant remediation measures negative publicity consequences laws regulations broad scope subject changing evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices impact ability obtain maintain regulatory approvals resulting impact business uncertain could material addition government price reporting payment regulations complex continually assessing methods calculate report pricing accordance obligations methodologies calculations inherently subjective may subject review challenge various government agencies may disagree interpretation government disagrees reported calculations may need restate previously reported data could subject additional financial legal liability also continues enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement patient support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products description government investigations related litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report subject risks significant safety issues arise marketed products product candidates additional studies conducted obtaining marketing approval products products used longer periods time many patients including patients underlying health problems taking medicines expect continue finding new issues related safety resistance drug interactions issues may require changes product labels additional warnings contraindications even narrowed indications halt product sales regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties patents proprietary rights important business part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others patent applications confidential period time filing may know competitors filed applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted patents covering existing compounds products processes likely file future may provide complete adequate protection filing patent applications factintensive complex process may file patent applications ultimately result patents patents provide adequate protection related product future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection addition may face criticism result legitimate use patent systems protect investments new useful innovations medicine generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report anda litigation related settlement license agreements cases may result loss exclusivity patents sooner would otherwise expect addition loss exclusivity may earlier expected settlement license agreements certain circumstances example settlement license agreements generic manufacturers typically include acceleration clauses permit generic entry agreedupon entry date certain circumstances generic manufacturers may continue challenge patents protecting products entry generic versions products may future lead market share price erosion found infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use products research activities description pending patent litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions could adversely affected trade secrets internal knowhow technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions face potentially significant liability increased expenses litigation government investigations relating products operations involved number litigation investigation disputerelated matters require us expend substantial internal financial resources time time matters require us pay significant monetary amounts including royalty payments past future sales expect matters continue require high level internal financial resources foreseeable future matters reduced expected continue reduce earnings require significant management attention addition testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise claims may exceed coverage description litigation investigation disputerelated matters see note commitments contingencies notes consolidated financial statements included part ii item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us operational risks business may future adversely affected outbreaks epidemic pandemic contagious diseases actual threatened outbreaks epidemic pandemic contagious diseases public health emergencies may significantly disrupt global operations adversely affect business financial condition results operations seen covid pandemic outbreaks result global supply chain logistics disruptions distribution constraints impact outbreak public health crisis results operations financial condition would depend numerous evolving factors could involve higher operating expenses lower demand products result governmental business individuals actions taken response event including quarantines travel restrictions interruptions healthcare services impact enrollment operation clinical trials limit patients ability willingness access seek care challenges associated safety employees safe occupancy job sites financial market volatility significant macroeconomic uncertainty global markets outbreak public health emergency also could amplify many risks described throughout risk factors section annual report face risks associated global operations global operations accompanied certain financial political economic risks including listed foreign currency exchange year ended december approximately product sales denominated foreign currencies significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar hedging program eliminate exposure currency fluctuations may adversely impacted us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation example see foreign currency exchange impact part ii item annual report discussion exposure movements foreign currency exchange rates primarily euro impacts foreign currency exchange net hedges year ended december interest rates inflation hold interestgenerating assets interestbearing liabilities including availableforsale debt securities senior unsecured notes credit facilities fluctuations interest rates including us federal reserves recent increases interest rates anticipated decreases could expose us increased financial risk addition high inflation seeing current economic environment adversely impacted may continue adversely impact business financial results antibribery subject us foreign corrupt practices act similar worldwide antibribery laws govern international operations respect payments government officials international operations heavily regulated require significant interaction foreign officials operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may statecontrolled manner different local custom possible certain practices may challenged laws addition internal control policies procedures may protect us reckless criminal acts committed employees agents enforcement activities antibribery laws could subject us administrative legal proceedings actions could result civil criminal sanctions including monetary penalties exclusion healthcare programs risks inherent conducting global business include restrictive government actions intellectual property assets nationalization expropriation imposition compulsory licenses similar actions including waiver intellectual property protections protective economic policies taken governments trade protection measures import export licensing requirements may result imposition trade sanctions similar restrictions us governments political instability disruption geographic region operate regardless cause including war terrorism social unrest political changes including china russia ukraine israel surrounding areas increasing use social media platforms modern technologies present new risks challenges inappropriate unauthorized use platforms result exposure sensitive data information damage brand reputation climate change related natural disasters well legal regulatory market measures address climate change negatively affect business operations many operations facilities including essential manufacturing rd commercializationdistribution activities located regions subject natural manmade disasters climate change earthquakes hurricanes rising sea levels flooding fires extreme heat drought extreme weather conditions efforts taken third parties prevent mitigate disasters public safety power shutoffs facility shutdowns severity frequency weatherrelated events amplified expected continue amplified climate change natural disasters caused future may cause damage andor disrupt operations may result material adverse effect business financial results example facility cork ireland conduct commercial manufacturing packaging labeling perform quality control testing final release many products temporarily suspended onsite operations result flooding caused storm babet october additionally corporate headquarters foster city certain rd manufacturing facilities located california seismically active region although business continuity plans contingencies place conduct periodic assessments natural disaster risk part overall enterprise risk management program major earthquake natural disaster result significant recovery time prolonged interruption operational business activities may required incur significant costs remedy effects natural disasters resume restore operations could adversely impact us suppliers third party manufacturers corporate partners face similar risks disruption operations could adverse effect manufacturing supply chain also see risks headings may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues addition growing concern regarding climate change resulted evolving legal regulatory landscape new requirements enacted prevent mitigate adapt implications climate change regulations differ across jurisdictions subject gilead many transitional risks including example new expanded carbon pricing taxes increased compliance costs restrictions greenhouse gas emissions investment new technologies increased carbon disclosure transparency investments data gathering reporting systems upgrades facilities meet new building codes redesign utility systems could increase companys operating costs including cost electricity energy suppliers thirdparty manufacturers corporate partners face similar transition risks may pass along increased costs company aspirations goals disclosures related environmental social governance esg matters expose us numerous risks including risks reputation stock price institutional individual investors increasingly using esg screening criteria determine whether gilead qualifies inclusion investment portfolios frequently asked investors stakeholders set ambitious esg goals provide new robust disclosure goals progress toward goals matters interest esg stakeholders response adapted tracking reporting corporate responsibility program various evolving esg frameworks established announced goals objectives related esg matters goal statements reflect current plans aspirations guarantees able achieve efforts accomplish accurately report goals objectives present numerous operational reputational financial legal risks could material negative impact including reputation stock price ability achieve goal objective including respect environmental diversity initiatives subject numerous risks many outside control examples risks include availability cost low noncarbonbased energy sources technologies evolving regulatory requirements affecting esg standards disclosures availability suppliers meet sustainability diversity standards ability recruit develop retain diverse talent labor markets impact organic growth acquisitions dispositions businesses operations standards tracking reporting esg matters relatively new harmonized continue evolve selection disclosure frameworks seek align various reporting standards may change time time may result lack consistent meaningful comparative data period period addition regulatory authorities may impose mandatory disclosure requirements respect esg matters example march us securities exchange commission sec proposed rule changes would require companies make certain climaterelated disclosures including information climaterelated risks greenhouse gas emissions certain climaterelated financial statement metrics also october california governor signed climaterelated financial risk act climate corporate data accountability act law impose significant mandatory climaterelated reporting requirements large companies business state processes controls may reflect evolving standards identifying measuring reporting esg matters immediately interpretation reporting standards may differ others standards may change time could result significant revisions goals reported progress achieving goals addition enhancements processes controls reflect evolving reporting standards may costly require additional resources esg practices meet evolving investor stakeholder expectations standards reputation ability attract retain employees attractiveness investment business partner acquiror could negatively impacted similarly failure perceived failure pursue fulfill goals targets objectives satisfy various reporting standards within timelines announce could also similar negative impacts expose us government enforcement actions private litigation depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline due specialized technical nature business failure attract develop retain highly qualified personnel could adversely impact us future success depend large part continued ability attract develop retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization ability also depends part well maintain strong workplace culture attractive employees addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit face competition personnel companies universities public private research institutions government entities organizations furthermore changes immigration work authorization laws regulations could make difficult employees work transfer one jurisdictions operate additionally periodically make adjustments reflect personnel needs response changing macroeconomic conditions market opportunities management changes acquisitions cost levels internal external considerations may adversely impact workplace culture ability retain incentivize employees failure successfully implement upgrade enterprise resource planning information systems could adversely impact business results operations periodically implement upgrade new enhanced enterprise resource planning erp information systems order better manage business operations align global organizations enable future growth implementation upgrade new business processes information systems requires commitment significant personnel training financial resources entails risks business operations successfully implement erp information systems improvements delays difficulties implementing systems may realize anticipated productivity improvements cost efficiencies may experience operational difficulties challenges effectively managing business could result quality issues reputational harm lost market revenue opportunities otherwise adversely affect business financial condition results operations example currently process implementing new erp information systems help us manage operations financial reporting costs risks inherent transition may include disruptions business continuity administrative technical problems interruptions delays sales manufacturing rd processes expenditure overruns delays paying suppliers employees data migration issues properly address mitigate issues could result increased costs diversion resources negatively impacting operating results ability effectively manage business additionally effectively implement erp system planned erp system operate intended effectiveness internal control financial reporting could negatively affected information system service interruptions breaches including significant cybersecurity incidents could give rise legal liability regulatory action data protection privacy laws adversely affect business operations dependent upon information technology systems infrastructure data including kite konnect platform critical maintain chain identity chain custody yescarta tecartus multitude complexity computer systems make inherently vulnerable service interruption destruction including caused failures system upgrades implementations user error network hardware failure malicious intrusion ransomware attack likewise data privacy cybersecurity incidents breaches employees others result exposure sensitive data including intellectual property trade secrets personal information employees patients customers business partners unauthorized persons public information systems thirdparty information systems rely suffer severe damage disruption shutdown including upgrades new implementations business continuity plans effectively resolve issues timely manner could experience delays reporting financial results may lose revenue profits result inability timely manufacture distribute invoice collect payments cybersecurity attacks incidents increasing frequency sophistication intensity malicious actors seek steal money gain unauthorized access destroy manipulate data disrupt operations attacks may recognized discovered significant period time well initial entry environment novel zeroday attacks launched patches available defenses readied malicious actors also increasingly developing methods avoid prevention detection alerting capabilities including employing counterforensic tactics making response activities difficult attacks incidents include example deployment harmful malware exploitation vulnerabilities computer viruses key loggers ransomware denialofservice social engineering means affect service reliability operations threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture like many companies experienced expect continue target cybersecurity incidents including data breaches temporary service interruptions cybersecurity incidents occur policy respond address accordance applicable governmental regulations legal requirements including cybersecurity protocols assurance efforts response cybersecurity incidents well investments protect information technology infrastructure data shield us significant losses brand reputational harm potential liability prevent future interruption breach systems cybersecurity incidents cause loss critical sensitive information including personal information could give rise legal liability regulatory action data protection privacy laws financial legal business reputational losses may result cybersecurity incident breach information technology systems regulators globally also imposing new data privacy security requirements including new greater monetary fines privacy violations example eus general data protection regulation gdpr established regulations regarding handling personal data noncompliance gdpr may result monetary penalties four percent worldwide revenue addition domestic data privacy security laws california consumer privacy act california privacy rights act laws may passed similarly introduce requirements respect personal information noncompliance laws may result liability private actions subject statutorily defined damages event certain data breaches enforcement changes new laws regulations associated enhanced protection personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate strategic financial risks subject risks associated engaging business acquisitions licensing arrangements collaborations options equity investments asset divestitures strategic transactions engaged may future engage transactions part business strategy may identify suitable transactions future may complete transactions timely manner costeffective basis including possibility governmental entity regulatory body may delay refuse grant approval consummation transaction successful making acquisition closing licensing arrangement collaboration products intellectual property technologies acquired licensed may successful may require significantly greater resources investments anticipated part annual impairment testing goodwill indefinitelived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles past may future need recognize impairment charges related products intellectual property technologies acquired licensed example result impairment analysis conducted following receipt data march phase tropics study evaluating trodelvy patients hormone receptor positive human epidermal growth receptor negative metastatic breast cancer recognized partial inprocess research development impairment charge condensed consolidated statements income similarly evaluating whether could required record impairment charge three months ended march connection phase evoke study evaluating sacituzumab govitecanhziy impairment charge unable reasonably estimate time could material impact results operations information see item managements discussion analysis financial condition results operations results operations inprocess research development impairments option structured deals assurance elect exercise option right possible disagreements uncertainties circumstances may arise including respect whether option rights appropriately triggered may hinder ability realize expected benefits example march waived exclusive option acquire pionyr immunotherapeutics september waived exclusive option acquire tizona therapeutics inc equity investments strategic partners connection collaborations arcus biosciences inc galapagos nv value equity investments may fluctuate decline value successful execution implementation transactions financial condition cash flows results operations may adversely affected stock price could decline paid substantial amounts cash incurred additional debt finance strategic transactions additional indebtedness lower cash balance could result downgrade credit ratings limit ability borrow additional funds refinance existing debt favorable terms increase vulnerability adverse economic industry conditions reduce financial flexibility continue capital investments stock repurchases dividend payments example result cash used debt issued connection acquisition immunomedics inc sp global ratings downgraded credit rating may adversely impacted failure overcome additional risks changes effective income tax rate could reduce earnings subject income taxes us various foreign jurisdictions due economic political conditions various countries actively considering made changes existing tax laws predict form timing changes effective tax rates affected changes mix earnings countries differing statutory tax rates changes valuation deferred tax assets liabilities introduction new taxes changes tax laws regulations administrative practices interpretations including us germany ireland also subject examination tax returns tax matters us internal revenue service tax authorities various foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions may adversely affected resolution one exposures reporting period item b unresolved staff comments applicable item c cybersecurity cybersecurity risk management strategy processes used assess identify manage material risks cybersecurity threats risk assessment management approach managing material risks cybersecurity threats informed part national institute standards technology nist cybersecurity framework though imply meet particular technical standards specifications requirements designed detect identify respond recover protect cybersecurity incidents security governance function includes key employees work information security legal privacy teams chief information officer cio chief information security officer ciso responsible establishing implementing cybersecurity policies procedures includes developing updating enterprise incident response plan irp managing incident response overseeing policy exceptions potential compensating controls additionally assess cybersecurity maturity annually using nist framework implement maintain controls designed evaluate improve cybersecurity program vulnerability assessments penetration tests needed also execute employee cybersecurity training awareness programs around various key cybersecurity topics including reporting incidents phishing ransomware remote working cloud security privileged access removable media process assessing identifying managing material risks cybersecurity threats integrated overall risk management process robust enterprise risk management erm program plays important role seeking manage address existing emerging risks including cybersecurity risks critical overall business goals objectives erm team updates ceo leadership team cybersecurity risks well potential impact likelihood potential mitigation plan status incident response dedicated information security team responsible managing coordinating incident response efforts team collaborates closely teams within company including teams within information technology legal privacy identifying analyzing responding cybersecurity incidents includes tracking cybersecurity incidents help identify related incidents cybersecurity incidents identified practice respond address utilizing incident classifications escalation protocols accordance applicable governmental regulations legal requirements irp prepare respond cybersecurity incidents process tested annual tabletop exercises help identify strengths areas improvement engagement third party advisors engage third party advisors including assessors cybersecurity consultants auditors assess validate enhance cybersecurity program benefit engaging third parties provide specialized skills knowledge tools resources third parties also help reduce costs increase efficiency improve quality mitigate risks review cybersecurity strategy trends threat landscape thirdparty service provider risk management process place oversee identify risks cybersecurity threats associated use key thirdparty service providers course engagement company uses external risk management software program identify assess monitor mitigate risks associated thirdparty relationships including cybersecurity risks vendor security assessment process evaluates key vendors appropriate assesses vendors controls security privacy business continuity thirdparty risks following evaluation company determines prioritizes risks based potential impact help inform appropriate level additional due diligence ongoing compliance monitoring thirdparty risk assessment crossfunctional effort involving enduser legal privacy information security teams material risks cybersecurity threats company identified risks cybersecurity threats materially affected us believe risks cybersecurity threats reasonably likely materially affect us including business strategy results operations financial condition long term like many companies experienced cybersecurity incidents including data breaches temporary service interruptions however end known cybersecurity incidents individually aggregate material impact nevertheless assurance efforts response cybersecurity incidents well investments protect infrastructure data shield us significant losses brand reputational harm potential liability prevent future interruption breach systems cybersecurity incidents cause loss critical sensitive information including personal information could give rise legal liability regulatory action data protection privacy laws additional information cybersecurity risks face see part item risk factors annual report heading information system service interruptions breaches including significant cybersecurity incidents could give rise legal liability regulatory action data protection privacy laws adversely affect business operations cybersecurity governance board oversight risks cybersecurity threats board directors plays important role overseeing cybersecurity risks board directors established oversight structure monitoring effectiveness risks related cybersecurity program designated board oversee cybersecurity information technology risks audit committee receives quarterly cybersecurity updates ciso chair audit committee meets ciso individually quarterly basis updates often address topics ongoing efforts improve cybersecurity posture operational metrics incident metrics mitigation actions may include key metrics related cybersecurity maturity risk reduction cybersecurity program health audit compliance activities audit committee updates board activities regularly scheduled board meeting risks related cybersecurity events provided board annual basis part overall erm update addition regular reporting significant cybersecurity risks may also escalated asneeded basis companys organizational structure accordance irp managements role assessing managing materials risks cybersecurity threats irp cybersecurity incidents escalated based defined incident severity management appropriate management including cio ciso involved assessing managing cybersecurity risks ciso reports cio turn reports chief financial officer turn reports ceo cio ciso participate global leadership team meetings years experience including three years company cio recognized externally leadership technology innovation industry provides strategic leadership companys organization ciso years cybersecurity experience large biopharmaceutical life sciences financial technology industries including ten years company responsible managing security architecture engineering technology operations monitoring incident response risk governance quality compliance company companys information security function comprised teams engage range cybersecurity activities security operations security engineering data privacy controls validation compliance audit readiness leaders team expected collaborate help increase visibility key issues alignment strategy noted companys irp includes standard processes escalating significant cybersecurity incidents management including ciso companys incident response team also coordinates external legal advisors cybersecurity forensic firms communication specialists outside advisors experts appropriate item properties corporate headquarters located foster city california house administrative manufacturing rd activities also administrative facilities raleigh north carolina parsippany new jersey washington dc rd facilities emeryville oceanside santa monica california seattle washington frederick maryland edmonton canada dublin ireland cambridge oxford united kingdom principal manufacturing facilities el segundo la verne oceanside santa monica california frederick maryland edmonton canada cork ireland hoofddorp netherlands information manufacturing facilities see item business manufacturing facilities global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites adequate suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities market information common stock traded nasdaq global select market symbol gild holders february approximately stockholders record common stock dividends years ended december paid quarterly dividends expect continue pay quarterly dividends although amount timing future dividends subject declaration board directors additional information included consolidated statements stockholders ' equity note subsequent events notes consolidated financial statements included item annual report securities authorized issuance equity compensation plans following table provides certain information respect equity compensation plans effect december number common shares remaining available future number common shares weightedaverage issuance equity issued upon exercise exercise price compensation plans outstanding options outstanding options excluding securities millions except exercise price rights rights reflected column plan category b c equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total includes million restricted stock units performance share units phantom shares awards exercise price included weightedaverage exercise price outstanding awards employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed us securities exchange commission incorporated reference filings securities act amended securities exchange act amended whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested issuer purchases equity securities first quarter board directors authorized billion stock repurchase program program fixed expiration purchases program may made open market privately negotiated transactions program obligate us repurchase specific number shares may amended suspended discontinued time started repurchases program december table summarizes stock repurchase activity three months ended december approximate dollar value shares total number shares may yet total number purchased part purchased shares purchased average price publicly announced programs thousands paid per share programs thousands millions october october november november december december total difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item reserved item managements discussion analysis financial condition results operations following discussion analysis intended provide material information around events uncertainties known management relevant assessment financial condition results operations gilead therefore read conjunction audited consolidated financial statements related notes thereto disclosures included part annual report including disclosures part item risk factors additional information related comparison results operations years included item managements discussion analysis financial condition results operations filed us securities exchange commission management overview gilead sciences inc including consolidated subsidiaries referred gilead company us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis coronavirus disease covid cancer operate countries worldwide headquarters foster city california continued advance portfolio broaden available therapies delivering continued growth hiv oncology product sales terms capital resources continued invest business research development rd pipeline acquisitions collaborations also continued provide shareholder returns dividends share repurchases key business updates following updates based press releases issued since last annual report readers encouraged review press releases available website wwwgileadcom content referenced website constitute part incorporated reference annual report virology announced phase oaktree trial obeldesivir nonhospitalized participants without risk factors developing severe covid meet primary endpoint improvement time symptom alleviation obeldesivir welltolerated large study population received us food drug administration fda european commission ec approval extend use veklury treat covid appropriate patients mild severe hepatic impairment well people severe renal impairment including dialysis announced collaboration assembly biosciences inc assembly advance research development novel antiviral therapies including herpesviruses chronic hepatitis b virus hbv chronic hepatitis delta virus hdv received full marketing authorization ec hepcludex bulevirtide treatment adults hdv compensated liver disease hepcludex initially granted conditional marketing authorization july bulevirtide remains approved treatment hdv european union eu approved us oncology announced full clinical hold placed fda magrolimab studies myelodysplastic syndromes acute myeloid leukemia pursue development magrolimab hematologic cancers announced phase evoke study trodelvy versus docetaxel previously treated metastatic nonsmall cell lung cancer meet primary endpoint overall survival statistically powered observed encouraging trend subgroup patients nonresponsive prior antipdl immunotherapy may potentially explore received fda approval yescartas label update include overall survival data phase zuma study showed statistically significant overall survival improvement yescarta secondline relapsed refractory rr large bcell lymphoma lbcl versus standard care received fda approval manufacturing process change resulting reduced median turnaround time yescarta us anticipated days days previously entered strategic collaboration arcellx inc arcellx codevelop cocommercialize cartddbcma latestage clinical asset development treatment patients relapsed refractory multiple myeloma later announced expansion arcellx collaboration include exercising option arcsparx aclx program multiple myeloma expanding scope existing anitocel collaboration include lymphomas equity investment announced exclusive license agreement compugen ltd compugen laterstage development commercialization novel preclinical anti il binding protein antibodies including com potential treat various tumor types announced collaboration tentarix biotherapeutics inc tentarix discover develop novel therapies across oncology inflammation using tentarixs proprietary tentacles platform received ec approval trodelvy monotherapy treatment adult patients unresectable metastatic hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer received endocrinebased therapy least two additional systemic therapies advanced setting announced fosun kite biotechnology co ltd joint venture us shanghai fosun pharmaceutical group co ltd approval axicabtagene ciloleucel trade name yikaida china national medical products administration treatment adult patients rr lbcl failed firstline immunochemotherapy relapsed within months firstline immunochemotherapy completed transfer yescartas marketing authorization japan daiichi sankyo co ltd gilead sciences kk announced acquisition xinthera inc xinthera adding additional pipeline assets including rights portfolio small molecule inhibitors targeting parp oncology well mk inflammatory diseases completed acquisition tmunity therapeutics inc tmunity clinical stage private biotech company provides preclinical clinical programs includes armored car technology platform potential applied variety car ts enhance antitumor activity well rapid manufacturing processes received fda approval trodelvy treatment adult patients unresectable locally advanced metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting inflammation announced entered definitive agreement acquire outstanding common stock cymabay therapeutics inc cymabay lead product candidate seladelpar investigational treatment primary biliary cholangitis announced amendment expanding collaboration agreement arcus biosciences inc arcus including research programs inflammatory diseases update domvanalimab collaboration program additional equity investment exercised option license investigational targeted protein degrader molecule nx gs nurix therapeutics inc gs potent selective oral irak degrader potential applications treatment rheumatoid arthritis inflammatory diseases issued billion aggregate principal amount senior unsecured notes registered offering comprised billion principal amount senior notes due billion principal amount senior notes due repaid debt billion key financial results year ended december millions except percentages per share amounts change total revenues net income attributable gilead diluted earnings per share attributable gilead total revenues decreased billion compared driven lower veklury sales largely offset higher hiv oncology sales net income attributable gilead billion diluted earnings per share attributable gilead compared billion diluted earnings per share attributable gilead increase primarily due lower inprocess research development iprd impairment expenses lower net unrealized losses equity investments higher interest income partially offset higher costs goods sold operating expenses lower revenues results operations revenues following table summarizes periodoverperiod changes total revenues year ended december year ended december millions except percentages us europe international total us europe international total change product sales hiv oncology cell therapy trodelvy liver disease hcv hbv hdv veklury total product sales royalty contract revenues total revenues see note revenues notes consolidated financial statements included item annual report disaggregation revenue product chronic hepatitis c virus hcv hiv following table summarizes periodoverperiod changes hiv product sales year ended december year ended december millions except percentages us europe international total us europe international total change biktarvy compleraeviplera descovy genvoya odefsey stribild truvada revenue share symtuza hiv total hiv represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company janssen see note collaborations arrangements notes consolidated financial statements included item annual report additional information includes atripla emtriva sunlenca tybost hiv product sales increased billion compared primarily due higher demand across treatment prevention addition higher average realized price favorable channel inventory dynamics particular biktarvy sales increased primarily reflecting higher demand including patients switching gilead hiv products well higher average realized price also descovy sales increased primarily driven favorable channel inventory dynamics higher demand oncology cell therapy cell therapy product sales increased billion compared primarily due increased yescarta demand treatment rr lbcl increased tecartus demand treatment rr adult acute lymphoblastic leukemia rr mantle cell lymphoma trodelvy trodelvy product sales increased billion compared primarily due higher demand new existing geographies liver disease liver disease product sales decreased billion compared primarily due unfavorable hcv pricing dynamics foreign exchange rates partially offset higher demand across hcv hdv hbv products veklury veklury product sales decreased billion compared primarily due lower demand driven lower rates covid related hospitalizations regions product sales decreased million compared primarily due loss exclusivity letairis grosstonet deductions substantial portion product sales subject significant discounts list price including government commercial rebates chargebacks well deductions including patient copay assistance cash discounts prompt payment distributor fees sales return provisions deductions product sales generally referred grosstonet deductions primarily function product sales volume product mix contractual statutory discounts estimated payer mix rebates chargebacks based contractual arrangements statutory requirements include amounts due payers healthcare providers various programs amounts may vary product payer individual plans providers qualified certain programs purchase products wholesalers distributors discount wholesalers distributors charge discount back us grosstonet deductions include patient copay assistance cash discounts prompt payment distributor fees pay inventory management agreements significant us wholesalers based contractuallydetermined fixed percentage sales sales return provisions grosstonet deductions totaled billion gross product sales compared billion gross product sales increase primarily due changes product mix decreases veklury product sales regions offset increased sales hiv oncology products changes payer mix billion billion gross product sales related rebates chargebacks billion primarily related patient copay assistance cash discounts prompt payment distributor fees sales return provisions billion billion gross product sales related rebates chargebacks billion primarily related patient copay assistance cash discounts prompt payment distributor fees sales return provisions current year grosstonet deductions percent gross product sales may indicative future results foreign currency exchange impact generally face exposure movements foreign currency exchange rates primarily euro use foreign currency exchange contracts hedge portion foreign currency exposures approximately product sales denominated foreign currencies respectively foreign currency exchange net hedges unfavorable impact total product sales million based comparison using foreign currency exchange rates royalty contract revenues royalty contract revenues decreased million compared primarily due higher milestone payments received lower royalty revenues due impact generic launches costs expenses following table summarizes periodoverperiod changes costs expenses year ended december millions except percentages change cost goods sold product gross margin bps research development expenses acquired inprocess research development expenses inprocess research development impairments selling general administrative expenses product gross margin product gross margin decreased compared primarily driven higher intangible asset amortization expenses related pretreated hrher metastatic breast cancer indication trodelvy following approval february restructuring expenses related changes manufacturing strategy resulted writeoffs certain manufacturing facilities related inventories costs totaling million product mix partially offset higher amortization inventory stepup charges research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation expense infrastructure materials supplies support costs research clinical studies performed contract research organizations collaboration partners outside services manage rd expenses identifying rd activities expect performed given period prioritizing efforts based scientific data probability successful technical development regulatory approval market potential available human capital resources considerations regularly review rd activities based unmet medical need necessary reallocate resources among internal rd portfolio external opportunities believe best support longterm growth business track total rd expenses product candidate therapeutic area development phase following table provides breakout expenses major cost type year ended december millions personnel infrastructure support costs clinical studies costs total research development expenses increased million compared personnel infrastructure support costs well clinical studies costs increased due clinical activities primarily related oncology virology including progression acceleration trials well new study launches acquired inprocess research development expenses acquired inprocess research development expenses recorded incurred reflect costs externallydeveloped iprd projects acquired directly transaction business combination alternative future use including upfront milestone payments related various collaborations costs rights iprd projects acquired inprocess research development expenses billion primarily comprised million associated arcellx collaboration million associated tmunity acquisition million associated xinthera acquisition million associated assembly collaboration million associated compugen licensing agreement acquired inprocess research development expenses million primarily comprised million associated acquisition mirobio ltd million associated collaboration dragonfly therapeutics inc million associated collaboration jounce therapeutics inc acquisition gs million associated collaboration macrogenics inc see note acquisitions note collaborations arrangements notes consolidated financial statements included item annual report additional information inprocess research development impairments inprocess research development impairments included million related partial impairment charge bulevirtide iprd intangible asset due change assumptions primarily around probability timing regulatory approval billion related partial impairment charge hrher iprd intangible asset december approximately billion assigned indefinitelived iprd intangible asset related trodelvy metastatic nonsmall cell lung cancer nsclc addition nsclc trodelvy explored potential investigational use range tumor types trop highly expressed gileads clinical development program metastatic nsclc includes multiple ongoing registrational phase studies several ongoing phase studies trodelvy first secondline indication january announced phase evoke study trodelvy evaluating sacituzumab govitecanhziy sg meet primary endpoint overall survival os previously treated nsclc however numerical improvement os favoring sg observed study including patients squamous nonsquamous histology safety profile trodelvy consistent prior studies addition threemonth difference median os favoring sg observed subgroup patients nonresponsive last prior antipdl therapy representing trial population analysis prespecified protocol alphacontrolled formal statistical testing continuing analyze data gilead intends explore potential pathways understand role sg may patients plan discuss data regulators key opinion leaders determine appropriate next steps believe new information represents indicator potential impairment first quarter result fair value indefinite lived iprd intangible asset related trodelvy may carrying value expect complete interim impairment assessment related iprd intangible asset first quarter extent estimated fair value less carrying value asset required record impairment charge consolidated statements income three months ended march impairment charge unable reasonably estimate time could material impact consolidated results operations selling general administrative expenses selling general administrative expenses recorded incurred consist primarily personnel costs facilities overhead costs sales marketing advertising expenses well general administrative costs related finance human resources legal administrative activities selling general administrative expenses increased million compared primarily due million litigation expense settlements certain plaintiffs hiv antitrust litigation second quarter increased commercial activities oncology hiv partially offset million nonrecurring charge associated termination trodelvy license collaboration agreement everest medicines interest expense income expense net following table summarizes periodoverperiod changes interest expense income expense net year ended december millions except percentages change interest expense income expense net nm nm meaningful interest expense remained relatively flat compared see note debt credit facilities notes consolidated financial statements included item annual report additional information income expense net included million interest income partially offset million net unrealized losses equity investments income expense net included million net unrealized losses equity investments partially offset million interest income income taxes following table summarizes periodoverperiod changes income tax expense year ended december millions except percentages change income income taxes income tax expense effective tax rate effective tax rate decreased compared primarily due decrease unrecognized tax benefits result reaching agreement tax authority certain tax positions organisation economic cooperation development framework implement global minimum corporate tax companies global revenues profits certain thresholds referred pillar two certain aspects effective january aspects effective january certain countries operate adopted pillar two legislation countries process introducing legislation implement pillar two expect pillar two material impact results operations liquidity capital resources liquidity capital resources regularly evaluate liquidity capital resources including access external capital ensure adequately efficiently finance operations liquidity cash cash equivalents marketable debt securities billion billion december respectively cash cash equivalents increased million december december following table summarizes cash flow activities year ended december millions net cash provided used operating activities investing activities financing activities effect exchange rate changes cash cash equivalents operating activities net cash provided operating activities derived adjusting net income noncash items changes operating assets liabilities net cash provided operating activities billion compared billion change primarily due higher income tax payments higher inventory operating spend includes hiv antitrust litigation settlement payments reduced effect nonrecurring payment billion settlement related bictegravir litigation higher collections investing activities net cash used investing activities billion compared billion change primarily due decrease acquisition spend including acquired iprd capital expenditures partially offset higher net purchases marketable debt equity securities financing activities net cash used financing activities billion compared billion utilized cash billion debt repayments billion dividend payments billion common stock repurchases partially offset billion proceeds issuance senior unsecured notes september net issuance costs utilized cash billion debt repayments billion dividend payments billion common stock repurchases capital resources believe existing capital resources including cash cash equivalents marketable debt securities revolving credit facility supplemented cash flows generated operations adequate satisfy capital needs foreseeable future december material cash requirements consisted primarily repayment outstanding borrowings income tax payments including remaining obligations onetime repatriation transition tax tax cuts jobs act purchases inventory operating lease obligations capital expenditures milestone payments related collaborative agreements see notes acquisitions collaborations arrangements debt credit facilities leases commitments contingencies income taxes notes consolidated financial statements included item annual report additional information enter certain unconditional purchase obligations capital expenditure projects commitments normal course business changes commitments year would material impact companys ability meet either shortterm longterm cash requirements future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements future dividends subject declaration board directors establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms may choose repay certain longterm debt obligations prior maturity dates based assessment current longterm liquidity capital requirements critical accounting estimates see note organization summary significant accounting policies notes consolidated financial statements included item annual report information significant accounting policies estimates involved preparation financial statements believe following reflect critical accounting estimates used preparation consolidated financial statements rebates chargebacks rebates chargebacks determined using complex estimation process requires significant judgment management part due lag date product sales date related rebates chargeback claims settled rebates chargebacks based contractual arrangements statutory requirements include amounts due payers healthcare providers various programs amounts may vary product payer individual plans rebates chargebacks estimated primarily based product sales expected payer mix discount rates require significant estimates judgment developing estimates rebates chargebacks consider following product sales including product mix pricing historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information following table summarizes consolidated activities ending balances rebates chargebacks accounts including adjustments made relating previous years sales result changes estimates balance decreaseincrease balance end millions beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total assess update estimates reporting period reflect actual claims current information historically actual rebates chargebacks claimed prior years varied less estimates however historical results indicative future results valuation intangible assets determining fair values intangible assets whether part business combination impairment assessment involves use probability weighted income approach discounts expected future cash flows present value requires use critical estimated inputs including identification product candidates sufficient substance requiring separate recognition estimates projected future cash flows including revenues operating profits related products product candidates example include significant inputs addressable patient population treatment duration projected market share probability technical regulatory success unapproved product candidates considering stages development time resources needed complete development approval product candidates appropriate discount rate based estimated weightedaverage cost capital companies profiles similar profile representing rate market participants would use value intangible assets life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets estimates subject uncertainty due high rate failure inherent discovery development new products delays occur development approval product launch processes unanticipated decisions made regulatory agencies advent competing products unexpected changes us global financial markets unanticipated events circumstances future events result adverse changes critical assumptions used determining fair value impairment charges intangible assets may recorded could material financial statements example recognized billion impairment charge related hrher iprd intangible asset related expected delay launch timing caused decrease market share assumptions based expected competitive environment legal contingencies party various legal actions certain significant matters described note commitments contingencies notes consolidated financial statements included item annual report critical inputs accruals recorded disclosures provided relation matters include probability certain outcome case determination whether exposure reasonably estimable amount potential exposure inputs subject uncertainty due changes legal facts circumstances case status proceedings applicable law views legal counsel views judges jury involved case upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes example second quarter recorded accrual million current liabilities consolidated balance sheets settlements certain plaintiffs hiv antitrust litigation paid second half income taxes subject income taxes us various foreign jurisdictions including ireland critical inputs determining provision income taxes related tax balances include forecasts future income expenses potential tax planning strategies determination probability certain tax positions sustained upon examination tax authorities inputs subject uncertainty due potential changes facts circumstances economic political conditions changes existing tax laws new regulations interpretations tax authorities changes conditions could material adverse impact results operations financial position see note income taxes notes consolidated financial statements included item annual report additional information item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit equity prices reduce certain risks enter various types foreign currency derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program may also enter transactions interest rate derivative hedges needed foreign currency exchange rate risk operations countries worldwide result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales enter foreign currency exchange forward contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million million respectively realized would negatively affected earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate credit risk portfolio availableforsale debt securities longterm borrowings exposed interest rate credit risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return fair value availableforsale debt securities subject change result potential changes market interest rates fair value portfolio availableforsale debt securities would significantly affected either increase decrease interest rates primarily due shortterm nature portfolio believe future market risks related securities material adverse impact financial position results operations liquidity senior unsecured notes fixed interest rates financial interest rate exposure fair value senior unsecured notes liability related future royalties part acquisition immunomedics inc exposed fluctuations interest rates current fair value debt portfolio liability related future royalties billion billion respectively fair value decrease interest rates increase fair value increase interest rates decrease additionally billion fiveyear revolving credit facility matures june loans revolving credit facility bear interest either term secured overnight financing rate plus applicable percentage ii base rate plus applicable percentage defined revolving credit facility agreement amounts outstanding revolving credit facility december currently financial interest rate exposure equity price risk hold shares common stock certain publicly traded biotechnology companies primarily connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings fair value equity securities approximately billion billion december respectively changes fair value equity securities impacted volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increased decreased fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm pcaob id audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matter critical audit matter communicated matter arising current period audit financial statements communicated required communicated audit committee relates accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matter alter way opinion consolidated financial statements taken whole communicating critical audit matter providing separate opinion critical audit matter accounts disclosures relates government commercial rebates description matter fully described note company estimates reductions revenues amounts payable payers healthcare providers united states various government commercial rebate programs period related sales occur rebates may vary product payer individual payer plans may known point sale estimated reductions revenue based product sales historical expected payer mix discount rates various estimated actual data adjusted current period expectations auditing companys estimated reductions revenue rebates complex involved significant judgment particularly assessing reasonableness estimated payer mix applied sales period estimate relies heavily historical data adjusted changes payer mix expectations time addressed evaluated tested design operating effectiveness companys internal controls managements estimation matter audit review reductions revenue rebate programs including controls assess payer mix assumption also tested completeness accuracy data utilized controls accuracy calculations supporting managements estimates test managements estimation methodology determining payer mix audit procedures included among others analytically evaluating managements estimates evaluating evidence contrary estimated amounts performing sensitivity analysis rates used estimates performing comparison actual payments related amounts accrued current prior years ernst young llp served companys auditor since san mateo california february gilead sciences inc consolidated balance sheets december millions except per share amounts assets current assets cash cash equivalents shortterm marketable debt securities accounts receivable net inventories prepaid current assets total current assets property plant equipment net longterm marketable debt securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued rebates current liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable deferred tax liability longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income year ended december millions except per share amounts revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses acquired inprocess research development expenses inprocess research development impairments selling general administrative expenses total costs expenses operating income interest expense income expense net income income taxes income tax expense net income net loss attributable noncontrolling interest net income attributable gilead basic earnings per share attributable gilead shares used basic earnings per share attributable gilead calculation diluted earnings per share attributable gilead shares used diluted earnings per share attributable gilead calculation see accompanying notes gilead sciences inc consolidated statements comprehensive income year ended december millions net income comprehensive income loss net net foreign currency translation gain loss availableforsale debt securities net unrealized gain loss net tax impact respectively reclassifications net income net tax impact respectively net change cash flow hedges net unrealized loss gain net tax impact respectively reclassifications net income net tax impact respectively net change comprehensive income loss net comprehensive income net comprehensive loss attributable noncontrolling interest net comprehensive income attributable gilead net see accompanying notes gilead sciences inc consolidated statements stockholders equity gilead stockholders equity common stock additional accumulated total paidin comprehensive retained noncontrolling stockholders millions except per share amounts shares amount capital income loss earnings interest equity balance december net income loss comprehensive income net issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock repurchase programs average price per share repurchases common stock employee tax withholding equity incentive plans dividends declared per share balance december net income loss comprehensive loss net issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock repurchase programs average price per share repurchases common stock employee tax withholding equity incentive plans dividends declared per share balance december net income loss comprehensive income net issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock repurchase programs average price per share repurchases common stock employee tax withholding equity incentive plans dividends declared per share balance december see accompanying notes gilead sciences inc consolidated statements cash flows year ended december millions operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes net loss equity securities acquired inprocess research development expenses inprocess research development impairment changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income tax assets liabilities net accrued liabilities net cash provided operating activities investing activities purchases marketable debt securities proceeds sales marketable debt securities proceeds maturities marketable debt securities acquisitions including inprocess research development net cash acquired purchases equity securities capital expenditures net cash used investing activities financing activities proceeds debt financing net issuance costs proceeds issuances common stock repurchases common stock repurchase programs repayments debt obligations payments dividends net cash used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies organization gilead sciences inc including consolidated subsidiaries referred gilead company us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis coronavirus disease covid cancer operate countries worldwide headquarters foster city california portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey sovaldi stribild sunlenca tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approved us also sell distribute authorized generic versions epclusa harvoni us separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements see note revenues summary disaggregated revenues product geographic region one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need chief executive officer chief operating decisionmaker codm manages allocates resources operations company entitywide basis managing allocating resources entitywide basis enables codm assess overall level resources available best deploy resources across functions research development rd projects based unmet medical need scientific data probability technical regulatory successful development market potential considerations necessary reallocate resources among internal rd portfolio external opportunities best support longterm growth business summary significant accounting policies basis presentation accompanying consolidated financial statements prepared accordance us generally accepted accounting principles include accounts gilead whollyowned subsidiaries variable interest entities vies primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal attributable economic ownership interest retained entities respective noncontrolling parties obtain variable interest another entity assess inception relationship upon occurrence certain significant events whether entity vie whether primary beneficiary vie based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various marketspecific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources estimates assessed period updated reflect current information actual results may differ significantly estimates beginning first quarter reclassified changes income taxes prepaid receivable prepaid expenses combine changes income taxes payable income tax assets liabilities net within operating activities consolidated statements cash flows believe presentation assists users financial statements better understand cash flow movements prior periods revised reflect change resulting reclassification million million prepaid expenses years ended december respectively certain amounts percentages herein may sum recalculate due rounding revenue recognition product sales recognize revenue product sales control product transfers customer generally upon shipment delivery certain cases upon corresponding sales customer third party revenues recognized net estimated rebates chargebacks patient copay assistance prompt pay discounts distributor fees sales return provisions related deductions deductions product sales referred grosstonet deductions estimated recorded period related product sales occur payment terms customers generally range days however payment terms differ jurisdiction customer instances type product revenues product sales net grosstonet deductions recorded extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated grosstonet deductions subsequently resolved taxes assessed governmental authorities collected customers excluded product sales expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects financing component shipping handling activities considered fulfillment activities separate performance obligation grosstonet deductions rebates chargebacks rebates chargebacks based contractual arrangements statutory requirements include amounts due payers healthcare providers various programs amounts may vary product payer individual plans providers qualified certain programs purchase products wholesalers distributors discount wholesalers distributors charge discount back us rebates chargebacks estimated primarily based product sales including product mix pricing historical estimated payer mix discount rates among inputs require significant estimates judgment assess update estimates reporting period reflect actual claims current information chargebacks payable direct customers generally classified reductions accounts receivable consolidated balance sheets rebates payable third party payers healthcare providers recorded accrued rebates consolidated balance sheets patient copay assistance copay assistance represents financial assistance qualified patients assisting prescription drug copayments required insurance accrual copay based estimate claims cost per claim expect receive associated inventory exists distribution channel period end cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractuallydetermined covenants maintenance agreedupon inventory levels distributor fees based contractuallydetermined fixed percentage sales allowance sales returns allowances made estimated sales returns customers recorded period related revenue recognized typically permit returns product damaged defective otherwise used customer us typically permit returns six months prior one year product expiration date outside us returns allowed certain countries limited basis estimates sales returns based primarily analysis historical product return patterns industry information reporting return rates similar products contractual agreement terms also take consideration known expected changes marketplace specific product royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur contract revenues recognized performance obligation satisfied research development expenses research development expenses recorded incurred consist primarily personnel costs including salaries benefits stockbased compensation expense infrastructure materials supplies support costs research clinical studies performed contract research organizations cros collaboration partners outside services time time enter development collaboration agreements share expenses collaborative partner record payments received collaborative partners share development costs reduction research development expenses clinical study costs significant component research development expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination payments make rd services prior services rendered recorded prepaid assets within prepaid current assets consolidated balance sheets expensed services provided acquired inprocess research development expenses acquired inprocess research development expenses recorded incurred reflect costs externallydeveloped inprocess research development iprd projects acquired directly transaction business combination alternative future use including upfront milestone payments related various collaborations costs rights iprd projects selling general administrative expenses selling general administrative expenses recorded incurred consist primarily personnel costs facilities overhead costs sales marketing advertising expenses well general administrative costs related finance human resources legal administrative activities advertising expenses within selling general administrative expenses including promotional expenses recorded incurred million million million years ended december respectively stockbased compensation provide stockbased compensation form various types equitybased awards including restricted stock units rsus performance share units psus stock options employee stock purchase plan international employee stock purchase plan together amended espp stockbased compensation expense based estimated fair value award grant date first date espp purchase period recognized requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience requisite service period could shorter vesting period employee retirement eligible employee terminates due death disability estimated fair value rsus based closing price common stock grant date psus depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant stock option espp awards estimated fair value based blackscholes option valuation model estimated inputs model include expected volatility based blend historical volatility common stock price along implied volatility traded options common stock ii expected term years based weightedaverage period awards expected remain outstanding using historical cancellation exercise data contractual terms vesting terms award iii riskfree interest rate based observed interest rates appropriate term stockbased awards iv expected dividend yield based history expectation dividend payments earnings per share basic earnings per share attributable gilead calculated based net income attributable gilead consolidated statements income divided weightedaverage number shares common stock outstanding period diluted earnings per share attributable gilead calculated based net income attributable gilead consolidated statements income divided weightedaverage number shares common stock dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents determined treasury stock method cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable debt securities marketable debt securities classified availableforsale recorded estimated fair values determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date unrealized gains losses availableforsale debt securities reported accumulated comprehensive income consolidated balance sheets realized point reclassified income expense net consolidated statements income regularly review investments declines fair value amortized cost basis determine whether impairment due creditrelated factors noncreditrelated factors review includes creditworthiness security issuers severity unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost bases determine portion unrealized loss due expected credit loss recognize loss amount income expense net corresponding allowance carrying value security hold portion unrealized loss related factors credit losses recognized accumulated comprehensive income interest amortization purchase premiums discounts also recorded income expense net consolidated statements income cost securities sold based specific identification method accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment estimated credit losses estimates allowance credit losses consider number factors including existing contractual payment terms individual customer circumstances historical payment patterns customers review local economic environment potential impact expected future customer payment patterns government funding reimbursement practices inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slowmoving excess otherwise unsaleable items obsolete slowmoving excess unsaleable items observed alternate uses inventory record writedown net realizable value charge cost goods sold consolidated statements income determination net realizable value requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors considered including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends equity securities equity securities readily determinable fair values including elected fair value option recorded fair market value unrealized gains losses included income expense net consolidated statements income equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer impairments adjustments recorded income expense net consolidated statements income investments entities significant influence meet requirements consolidation elected fair value option use equity method accounting share underlying income loss entities reported income expense net consolidated statements income investments equity securities classified prepaid current assets longterm assets consolidated balance sheets generally depending marketability whether securities subject lockup provisions regularly review securities indicators impairment property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term see impairment longlived assets additional information leases determine arrangement contains lease inception classify lease operating financing rightofuse assets lease liabilities recognized commencement date based present value lease payments lease term noncancelable period stated contract adjusted options extend terminate reasonably certain exercise option rightofuse assets adjusted prepaid lease payments lease incentives initial direct costs incurred operating lease expense minimum lease payments recognized straightline basis lease term account lease nonlease components lease agreements single lease component determining lease assets liabilities addition recognize rightofuse assets liabilities leases lease terms one year less operating leases provide implicit interest rate generally utilize collateralized incremental borrowing rate applied portfolio approach relevant based information available commencement date determine lease liability acquisitions including goodwill intangible assets contingent consideration account business combinations using acquisition method accounting generally requires assets acquired including iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess consideration fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period may one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred intangible assets related iprd projects considered indefinitelived abandonment completion associated rd efforts generally occurs regulatory approval obtained goodwill indefinitelived intangible assets amortized instead tested impairment annually frequently events changes circumstances indicate likely assets impaired intangible assets finite useful lives amortized estimated useful lives primarily straightline basis also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration amortization see impairment long lived assets additional information determining initial fair value intangible asset quantitative analysis required determine impairment use probabilityweighted income approach discounts expected future cash flows present value using discount rate based estimated weightedaverage cost capital companies profiles similar represents rate market participants would use value intangible assets cash flow models require use level fair value measurements inputs including estimated revenues example include significant inputs addressable patient population treatment duration projected market share assessment assets life cycle competitive trends impacting asset costs probability technical regulatory success among factors connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date reporting period thereafter revalue obligations record increases decreases fair value consolidated statements income time payment made increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates determine net assets acquired meet definition business combination acquisition method accounting transaction accounted asset acquisition therefore goodwill recorded contingent consideration generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date subsequent milestone payments expensed incurred consolidated statements income unless alternative future use impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may indicate carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset useful life carrying amount asset asset group asset asset group determined impaired excess carrying value asset asset group estimated fair value recognized impairment loss derivatives recognize derivative instruments either assets liabilities fair value consolidated balance sheets unrealized changes fair value derivatives designated part hedge transaction recorded accumulated comprehensive income hedges related forecasted product sales unrealized gains losses accumulated comprehensive income reclassified product sales consolidated statements income respective hedged transactions affect earnings changes fair value derivatives part hedge transaction recorded period income expense net consolidated statements income using regression analysis assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income contingencies recognize accruals loss contingencies extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible disclose possible loss range loss amount loss estimated time income taxes income tax provision computed liability method significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made recognize tax benefit uncertain tax position likely tax position sustained upon examination tax authorities based technical merits position tax benefit recognized consolidated financial statements particular tax position based largest benefit likely realized amount unrecognized tax benefits utb adjusted appropriate changes facts circumstances significant amendments existing tax law new regulations interpretations tax authorities new information obtained tax examination resolution examination recognize accrued interest penalties appropriate related utb income tax expense consolidated statements income elected account tax global intangible lowtaxed income enacted part tax cuts jobs act component tax expense period tax incurred stock repurchases use par value method accounting stock repurchases made repurchase programs par value method record par value shares repurchased common stock historical issuance cost par value shares repurchased additional paidin capital excess cost shares repurchased two amounts recorded retained earnings foreign currency translation transactions consolidated financial statements presented us dollars functional currency foreign subsidiaries local currency revenues expenses gains losses nonus dollar functional currency entities translated us dollars using average currency exchange rates period assets liabilities entities translated using exchange rates approximate rate balance sheet date foreign currency translation adjustments recorded component accumulated comprehensive income consolidated balance sheets foreign currency transaction gains losses transactions denominated functional currency recorded income expense net consolidated statements income fair value measurements apply fair value accounting financial nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks determine fair value using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities active markets quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation recently issued accounting pronouncements yet adopted november financial accounting standards board fasb issued accounting standards update asu segment reporting topic improvements reportable segment disclosures asu requires incremental annual quarterly disclosures segment measures profit loss well significant segment expenditures also requires public entities single reportable segment provide segment disclosures required amendments update existing segment disclosures topic guidance applied retrospectively plan adopt beginning annual report filed early quarterly annual reports thereafter single reportable segment expect adoption standard result increased disclosures notes consolidated financial statements december fasb issued asu income taxes topic improvements income tax disclosures asu requires incremental annual disclosures around income tax rate reconciliations income taxes paid related disclosures guidance requires prospective application permits retrospective application prior periods presented plan adopt beginning annual report filed early expect adoption standard result increased disclosures notes consolidated financial statements revenues disaggregation revenues following table summarizes total revenues year ended december year ended december year ended december millions us europe international total us europe international total us europe international total product sales hiv biktarvy compleraeviplera descovy genvoya odefsey stribild truvada revenue share symtuza hiv total hiv oncology cell therapy tecartus yescarta total cell therapy trodelvy total oncology liver disease chronic hepatitis c virus hcv ledipasvir sofosbuvir sofosbuvirvelpatasvir hcv total hcv chronic hepatitis b virus hbv chronic hepatitis delta virus hdv vemlidy viread hbvhdv total hbvhdv total liver disease veklury ambisome letairis total total product sales royalty contract revenues total revenues represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company janssen see note collaborations arrangements additional information includes atripla emtriva sunlenca tybost amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes hepcludex hepsera includes cayston jyseleca ranexa zydelig revenues major customers following table summarizes revenues customers individually accounted total revenues year ended december percentage total revenues cardinal health inc cencora inc formerly known amerisourcebergen corporation mckesson corporation revenues recognized performance obligations satisfied prior years following table summarizes revenues recognized performance obligations satisfied prior years year ended december millions revenue share janssen royalties licenses intellectual property changes estimates see note collaborations arrangements additional information contract balances following table summarizes contract balances december millions contract assets contract liabilities consists unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation generally results receipt advance payment performance contract fair value measurements following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy december december millions level level level total level level level total assets availableforsale debt securities us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities equity securities money market funds publicly traded equity securities deferred compensation plan foreign currency derivative contracts total liabilities liability myr gmbh myr contingent consideration deferred compensation plan foreign currency derivative contracts total publicly traded equity securities include investments galapagos nv galapagos million arcellx inc arcellx million december subject contractual sale restrictions august june respectively see note collaborations arrangements additional information level inputs availableforsale debt securities availableforsale debt securities estimate fair values reviewing trading activity pricing measurement date taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs foreign currency derivative contracts foreign currency derivative contracts maturities months less counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts utilizing incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates secured overnight financing rate sofr swap rates inputs applicable observable commonly quoted intervals senior unsecured notes following table summarizes total estimated fair value carrying value senior unsecured notes determined using level inputs based quoted market values december millions fair value carrying value level inputs contingent consideration liability connection first quarter acquisition myr subject potential contingent consideration payment million subject customary adjustments revalued reporting period using probabilityweighted scenarios us food drug administration fda approval hepcludex related contingency resolved following table summarizes change fair value contingent consideration liability year ended december millions beginning balance changes valuation assumptions effect foreign exchange remeasurement ending balance included research development expenses consolidated statements income changes primarily related changes assumptions around probability timing regulatory approval included income expense net consolidated statements income included longterm obligations consolidated balance sheets december respectively liability related future royalties recorded liability related future royalties part fourth quarter acquisition immunomedics inc immunomedics subsequently amortized using effective interest method remaining estimated life see note debt credit facilities additional information following table summarizes fair value carrying value liability related future royalties december millions fair value carrying value nonrecurring fair value measurements recorded million writeoff finitelived intangible asset related filgotinib discussed note goodwill intangible assets well million writeoff manufacturing assets related changes manufacturing strategy discussed note financial information charges recorded within cost goods sold consolidated statements income recorded partial impairment charge million billion respectively related certain iprd assets discussed note goodwill intangible assets fair value level transfers transfers level level level periods presented availableforsale debt securities equity securities availableforsale debt securities following table summarizes availableforsale debt securities december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated millions cost gains losses fair value cost gains losses fair value us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities total following table summarizes information related availableforsale debt securities continuous unrealized loss position classified length time december less months months longer total gross gross gross unrealized estimated fair unrealized estimated fair unrealized estimated millions losses value losses value losses fair value us treasury securities us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total december less months months longer total gross gross gross unrealized estimated unrealized estimated fair unrealized estimated millions losses fair value losses value losses fair value us treasury securities us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total allowance credit losses recognized investments unrealized losses december unrealized losses primarily driven broader change interest rates adverse conditions identified would prevent issuer making scheduled principal interest payments currently intend sell likely required sell investments recovery amortized cost bases following table summarizes classification availableforsale debt securities consolidated balance sheets december millions cash cash equivalents shortterm marketable debt securities longterm marketable debt securities total following table summarizes availableforsale debt securities contractual maturity december millions amortized cost fair value within one year one year five years five years ten years ten years total equity securities following table summarizes classification equity securities consolidated balance sheets december millions equity securities measured fair value cash cash equivalents prepaid current assets longterm assets equity method investments equity investments without readily determinable fair values longterm assets total equity method investments galapagos arcus biosciences inc arcus elected applied fair value option believe best reflects underlying economics investments investment galapagos subject certain lockup provisions august classified prepaid current assets longterm assets december million million respectively investment arcus classified prepaid current assets december million million respectively unrealized gains losses following table summarizes net unrealized gains losses equity securities still held respective balance sheet dates included income expense net consolidated statements income year ended december millions net unrealized losses equity securities still held related party transaction years ended december gilead donated certain equity securities fair value gilead foundation california nonprofit public benefit corporation foundation foundation related party certain officers also serve directors foundation donation expense million million recorded within selling general administrative expenses consolidated statements income years ended december respectively derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro manage risk hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes derivative instruments use hedge exposures certain monetary assets liabilities denominated nonfunctional currency designated hedges derivative instruments use hedge exposures forecasted product sales designated cash flow hedges maturities months less held foreign currency exchange contracts outstanding notional amounts billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts consolidated balance sheets gross basis following table summarizes classification fair values derivative instruments including potential effect offsetting december derivative assets derivative liabilities millions classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities total derivatives designated hedges total derivatives presented gross consolidated balance sheets gross amounts offset consolidated balance sheets derivative financial instruments cash collateral received pledged net amount legal offset december derivative assets derivative liabilities millions classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities total derivatives designated hedges total derivatives presented gross consolidated balance sheets gross amounts offset consolidated balance sheets derivative financial instruments cash collateral received pledged net amount legal offset following table summarizes effect derivative contracts consolidated financial statements year ended december millions derivatives designated hedges net loss gain recognized accumulated comprehensive income loss net gain loss reclassified accumulated comprehensive income loss product sales derivatives designated hedges net gain recognized income expense net majority gains losses related hedged forecasted transactions reported accumulated comprehensive income loss december expected reclassified product sales within months discontinuances cash flow hedges years presented cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows acquisitions cymabay february entered definitive agreement acquire outstanding common stock cymabay therapeutics inc cymabay lead product candidate seladelpar investigational treatment primary biliary cholangitis approximately billion terms merger agreement whollyowned subsidiary gilead promptly commence tender offer acquire outstanding shares cymabays common stock price per share cash following successful completion tender offer gilead acquire remaining shares tendered offer second step merger price tender offer consummation tender offer subject minimum tender least majority thenoutstanding cymabay shares expiration termination waiting period hartscottrodino antitrust improvements act customary conditions gilead plans pay cash consideration transaction tender offer subject financing condition upon closing cymabay become whollyowned subsidiary cymabays lead program seladelpar investigational oral selective peroxisome proliferatoractivated receptor delta agonist shown regulate critical metabolic liver disease pathways based data evaluating efficacy tolerability profile seladelpar participants across phase phase studies new drug application seladelpar submitted fda december xinthera may closed agreement acquire xinthera inc xinthera privately held biotechnology company focused small molecule drugs treat cancer immunologic diseases approximately million cash consideration net cash acquired result xinthera became whollyowned subsidiary accounted transaction asset acquisition recorded million charge acquired inprocess research development expenses consolidated statements income remaining purchase price relates various assets acquired liabilities assumed agreement former shareholders xinthera eligible receive performancebased development regulatory milestone payments approximately million million paid charged primarily acquired inprocess research development expenses tmunity february closed agreement acquire tmunity therapeutics inc tmunity clinicalstage private biotechnology company focused next generation car ttherapies technologies terms agreement acquired outstanding shares tmunity already owned gilead approximately million cash consideration result tmunity became whollyowned subsidiary accounted transaction asset acquisition recorded million charge acquired inprocess research development expenses consolidated statements income remaining purchase price relates various assets acquired liabilities assumed consisting primarily deferred tax assets agreement former shareholders tmunity university pennsylvania eligible receive mix approximately billion potential future payments upon achievement certain development regulatory salesbased milestones well royalty payments sales million charged acquired inprocess research development expenses paid january mirobio september acquired outstanding share capital mirobio ltd mirobio privatelyheld ukbased biotechnology company focused restoring immune balance agonists targeting immune inhibitory receptors million cash result mirobio became whollyowned subsidiary accounted transaction asset acquisition recorded million charge acquired inprocess research development expenses consolidated statements income remaining purchase price relates various assets acquired liabilities assumed myr first quarter completed acquisition myr german biotechnology company myr focuses development commercialization therapeutics treatment hdv acquisition provided gilead hepcludex conditionally approved european medicines agency ema july treatment chronic hdv infection adults compensated liver disease upon closing myr became whollyowned subsidiary gilead financial results myr included consolidated financial statements date acquisition aggregate consideration acquisition billion billion primarily consisted billion billion paid upon closing contingent consideration million subject customary adjustments representing potential future milestone payment upon fda approval hepcludex fair value contingent liability estimated using probabilityweighted scenarios fda approval million acquisition date see note fair value measurements additional information acquisition myr accounted business combination using acquisition method accounting following table summarizes estimated fair values assets acquired liabilities assumed acquisition date millions amount intangible assets finitelived intangible asset acquired iprd deferred income taxes net assets liabilities net total identifiable net assets goodwill total consideration intangible assets finitelived intangible asset million represents estimated fair value hepcludex hdv europe acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable hepcludex hdv europe discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired iprd consists hepcludex hdv regions without regulatory approval including united states estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs level fair value measurement disclosure guidance estimate probabilityweighted net cash flows attributable asset discount rate discount rate used represents estimated rate market participants would use value intangible asset deferred income taxes net deferred tax liability based upon difference estimated financial statement basis tax basis net assets acquired estimate final preacquisition net operating losses myr goodwill excess consideration transferred fair values assets acquired liabilities assumed million recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized myr expected deductible income tax purposes oneyear measurement period completed first quarter adjustments recorded fair values assets acquired liabilities assumed million see note goodwill intangible assets additional information collaborations arrangements enter licensing strategic collaborations similar arrangements third parties research development commercialization certain products product candidates arrangements may involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities financial terms arrangements may include nonrefundable upfront payments expense reimbursements payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements equity investments development milestone payments recorded consolidated statements income incurred generally corresponding events become probable regulatory milestone payments capitalized intangible assets amortized cost goods sold term respective collaboration arrangement certain payments contingent upon occurrence various future events high degree uncertainty arcellx january closed agreement enter global strategic collaboration arcellx public company codevelop cocommercialize arcellxs lead latestage product candidate cartddbcma treatment patients relapsed refractory multiple myeloma potential future next generation autologous nonautologous products december expanded scope collaboration include lymphomas exercised option negotiate license arcellxs arcsparx program aclx multiple myeloma conjunction collaboration agreements recorded combined million charge acquired inprocess research development expenses consolidated statements income primarily related upfront payments well combined equity investment million equity investment subject lockup provisions june included longterm assets consolidated balance sheets december companies share development clinical trial commercialization costs cartddbcma jointly commercialize product split us profits outside us commercialize product arcellx receive royalties sales arcellx eligible receive performancebased development regulatory milestone payments billion related cartddbcma potential future nextgeneration autologous product potential future nonautologous product commercial milestone payments profit split payments copromoted products royalties least portion worldwide net sales depending whether arcellx opts copromote future products additional future products developed arcellx would eligible receive additional milestone payments profit split payments copromoted products royalties least portion worldwide net sales depending whether arcellx opts copromote additional future products well dragonfly april entered strategic research collaboration agreement dragonfly collaboration agreement dragonfly therapeutics inc dragonfly develop natural killer nk cell engagerbased immunotherapies oncology inflammation indications terms dragonfly collaboration agreement received exclusive worldwide license dragonfly ttargeting investigational immunotherapy program df well options completion certain preclinical activities license exclusive worldwide rights develop commercialize additional nk cell engager programs using dragonfly trispecific nk engager platform upon closing dragonfly collaboration agreement made million upfront payment dragonfly made additional million payment related target selection connection august amendment agreement recorded acquired inprocess research development expenses consolidated statements income year ended december july mutually agreed terminate df program exercise options additional nk cell engager programs dragonfly would eligible receive optin payments performancebased development regulatory commercial milestone payments royalties worldwide net sales optioned programs merck march entered license collaboration agreement merck sharp dohme corp subsidiary merck co inc merck jointly develop commercialize longacting investigational treatments hiv combine gileads investigational capsid inhibitor lenacapavir mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir formulations potentially added collaboration mutually agreed collaboration initially focused longacting oral injectable formulations terms agreement amended gilead merck mostly share global development commercialization costs respectively across oral injectable formulation programs longacting oral products approved gilead would lead commercialization us merck would lead commercialization european union eu rest world longacting injectable products approved merck would lead commercialization us gilead would lead commercialization eu rest world terms agreement gilead merck would jointly promote combination products us certain major markets successful would share global product revenues merck equally product revenues surpass certain predetermined per formulation revenue tiers upon passing billion net product sales oral combination given calendar year share revenue would increase revenues threshold calendar year upon passing billion net product sales injectable combination given calendar year share revenue increase revenues threshold calendar year reimbursements rd costs merck recorded within research development expenses consolidated statements income expenses recognized agreement material years ended december revenues recognized agreement years ended december also option license certain mercks investigational oral integrase inhibitors develop combination lenacapavir reciprocally merck option license certain gileads investigational oral integrase inhibitors develop combination islatravir company may exercise option investigational oral integrase inhibitor company within first five years execution agreement following completion first phase clinical trial integrase inhibitor upon exercise option companies split development costs revenues unless nonexercising company decides opt case nonexercising company paid royalty arcus may entered transaction arcus publicly traded oncologyfocused biopharmaceutical company included entry option license collaboration agreement collaboration agreement gilead right opt current future clinicalstage product candidates ten years following closing transaction common stock purchase agreement investor rights agreement together subsequently amended stock purchase agreements november exercised options three arcus clinical stage programs amended collaboration agreement option exercise amendment transaction closed december triggering collaboration optin payments million waiving million option continuation payment would due arcus third quarter net option charge million included within acquired inprocess research development expenses consolidated statements income year ended december collaboration optin payments million recorded current liabilities consolidated balance sheets december paid arcus january payments arcus included within net cash used investing activities consolidated statements cash flows first quarter may amended collaboration agreement initiate research programs four targets jointly selected parties applicable inflammatory diseases part amendment paid million upfront fee charged acquired inprocess research development expenses consolidated statements income gilead may exercise option license program two separate prespecified time points gilead exercises option earlier time point first two target programs arcus would eligible receive million future option milestone payments tiered royalties optioned program option exercise gilead four target programs parties would rights co develop share global development costs cocommercialize share profits us optioned programs amended collaboration agreement companies codevelop share global costs related clinical programs recorded million million costs research development expenses consolidated statements income years ended december respectively optioned molecules achieve regulatory approval companies cocommercialize equally share profits us gilead hold exclusive commercialization rights outside us subject rights arcuss existing collaboration partners pay arcus tiered royalties percentage net sales ranging mid teens low twenties amended collaboration agreement may also pay additional million option fourth sixth eighth anniversaries agreement unless terminated early maintain rights opt future arcus programs duration contact term stock purchase agreements right purchase arcus additional shares maximum outstanding voting stock arcus fiveyear period ending third quarter also subject threeyear standstill restricting certain activity part expired second quarter made various purchases shares since original closing agreement following latest purchase second quarter owned total million shares represented approximately issued outstanding voting stock arcus time december two designees arcus board directors january announced amendment collaboration agreement arcus made additional equity investment arcus million increasing ownership amended collaboration agreement agreed pay million fourth anniversary option continuation fee also increased number designees arcus board directors three pionyr june entered transaction pionyr immuotherapeutics pionyr privately held company pursuing novel biology field immuno oncology included entry two separate agreements one related initial acquisition equity interest pionyr providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock pionyr pionyr merger option agreements rd service agreement march terminated rd service agreement waived exclusive option acquire pionyr certain rights pionyr merger option agreements recorded million charge income expense net consolidated statements income writing full value option previously recorded longterm assets consolidated balance sheets previously accounted investment pionyr using equity method accounting equity interest provided us ability exercise significant influence pionyr carrying value equity method investment pionyr zero december august pionyr acquired ikena oncology inc ikena publicly traded company equity interest converted shares ikena stock tizona july entered transaction tizona therapeutics inc tizona privately held company developing cancer immunotherapies included entry two separate agreements one related initial acquisition equity interest tizona providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock tizona tizona merger option agreements development agreement september terminated development agreement waived exclusive option acquire tizona certain rights tizona merger option agreements recorded million charge income expense net consolidated statements income writing full value option previously recorded longterm assets consolidated balance sheets account investment tizona using equity method accounting equity interest provides us ability exercise significant influence tizona carrying value equity method investment tizona zero december galapagos filgotinib collaboration october amended previous agreement galapagos clinicalstage biotechnology company based belgium related development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications terminate global development costsharing arrangement galapagos obligation pay tiered royalties us net sales europe result wrote remaining million balance related finitelived intangible asset discussed note goodwill intangible assets also previously paid galapagos million approximately million related agreement terminate galapagos right receive future milestone payments relating filgotinib europe full amount expensed million approximately million paid million approximately million paid global collaboration august closed option license collaboration agreement galapagos collaboration agreement subscription agreement galapagos subscription agreement galapagos pursuant parties entered global collaboration covers galapagos current future product portfolio filgotinib pursuant galapagos subscription agreement purchased million new ordinary shares galapagos issued warrants confer right subscribe time time number new shares issued galapagos sufficient bring number shares owned us issued outstanding shares time exercises currently million shares approximately shares issued outstanding time last purchase subject year standstill restricting ability acquire voting securities galapagos exceeding issued outstanding voting securities galapagos agreed without prior consent galapagos dispose equity securities galapagos prior second anniversary closing galapagos subscription agreement dispose equity securities galapagos thereafter fifth anniversary closing galapagos subscription agreement disposal would less thenissued outstanding voting securities galapagos subject certain exceptions termination events april amended galapagos subscription agreement extend initial lockup provision certain galapagos shares august august respect programs galapagos current future pipeline exercise option program pay million option exercise fee per program addition galapagos receive tiered royalties ranging net sales territories galapagos product optioned us exercise option program parties share equally development costs mutually agreed commercialization costs incurred subsequent exercise option may terminate collaboration entirety programbyprogram countrybycountry basis advance notice well following customary termination events two designees appointed galapagos board directors janssen compleraeviplera odefsey entered license collaboration agreement janssen develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved us eu sold brand name complera us eviplera eu agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside us neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues including major markets sales products included product sales janssens share revenues included cost goods sold consolidated statements income cost goods sold relating janssens share million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide gilead compounds combination approved us eu july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales sales products included product sales consolidated statements income royalties due japan tobacco included cost goods sold consolidated statements income royalty expenses recognized million million million years ended december respectively terms agreement paid japan tobacco million cash recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause everest april everest medicines everest immunomedics entered agreement granting everest exclusive license develop commercialize trodelvy greater china south korea singapore indonesia philippines vietnam thailand malaysia mongolia territories gilead subsequently acquired immunomedics october assumed everest license supply agreement provided certain sales milestones royalties payments made gilead recorded million finitelived asset part purchase accounting fourth quarter reacquired development commercialization rights trodelvy everest terminated previous agreement terms new agreement gilead made million upfront termination payments everest million made million made addition everest eligible receive million potential additional payments upon achievement certain regulatory commercial milestones accounted new agreement contract termination includes reacquisition commercial rights settlement preexisting relationship everest result recorded expense million selling general administrative expenses consolidated statements income year ended december primarily represents upfront costs writeoff remaining value preexisting asset related prior agreement simultaneously recorded acquired finitelived asset fair value million commercial rights reacquired products approved territories abingworth december entered arrangement funds managed abingworth llp abingworth receive million cofund development costs trodelvy nonsmall cell lung cancer substantive transfer risk financial partner development funding recognized us obligation perform contractual services received million abingworth recognizing funding reduction research development expenses using attribution model period related expenses successful upon regulatory approval us specified indication abingworth eligible receive approvalbased fixed milestone payment million royalties based applicable net sales property plant equipment following table summarizes property plant equipment net asset type december millions land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation total wrote million property plant equipment related changes manufacturing strategy writeoffs related primarily buildings improvements related equipment determined fully impaired based difference fair value carrying amount result decision longer utilize facilities following table summarizes property plant equipment net geography december millions us international total individual international locations accounted less total balances goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill december millions beginning balance measurement period adjustments ending balance goodwill decreased million result finalizing amount acquired net operating losses myr resulted decrease net deferred tax liability acquired impairment losses december accumulated goodwill impairment losses intangible assets following table summarizes intangible assets net december december gross foreign currency gross foreign currency carrying accumulated translation net carrying carrying accumulated translation net carrying millions amount amortization adjustment amount amount amortization adjustment amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel intangible asset trodelvy intangible asset hepcludex total finitelived assets indefinitelived assets iprd total intangible assets february fda granted approval trodelvy use adult patients unresectable locally advanced metastatic hrher breast cancer received endocrine based therapy least two additional systemic therapies metastatic setting accordingly related iprd intangible asset billion reclassified finitelived assets first quarter fourth quarter connection agreement terminate right receive royalties galapagos related net sales filgotinib europe wroteoff remaining million balance related intangible asset see note collaborations arrangements additional information fourth quarter due change anticipated timing fda approval recognized million partial impairment bulevirtide iprd intangible asset process research development impairments consolidated statements income remaining iprd intangible asset balance december comprised billion nonsmall cell lung cancer nsclc indications trodelvy billion bulveritide amortization expense aggregate amortization expense related finitelived intangible assets billion billion billion years ended december respectively primarily included cost goods sold consolidated statements income following table summarizes estimated future amortization expense associated finitelived intangible assets december millions amount thereafter total impairment assessments indicators impairment noted years ended december except described intangible assets table iprd impairment weightedaverage discount rates used quantitative assessments iprd intangible assets years assessment described respectively january announced phase evoke study trodelvy evaluating sacituzumab govitecanhziy sg meet primary endpoint overall survival os previously treated nsclc believe new information represents indicator potential impairment first quarter result fair value indefinitelived iprd intangible asset related trodelvy may carrying value expect complete interim impairment assessment related iprd intangible asset first quarter extent estimated fair value less carrying value asset required record impairment charge consolidated statements income three months ended march impairment charge unable reasonably estimate time could material impact consolidated results operations iprd impairment connection acquisition immunomedics allocated portion purchase price acquired iprd intangible assets approximately billion assigned iprd intangible assets related trodelvy treatment patients hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer march received data phase tropics study evaluating trodelvy patients hrher metastatic breast cancer received prior endocrine therapy cyclindependent kinase inhibitors two four lines chemotherapy thirdline plus patients based evaluation study results connection preparation financial statements first quarter updated estimate fair value hrher iprd intangible asset billion march estimate fair value used probability weighted income approach discounts expected future cash flows present value requires use level fair value measurements inputs including estimated revenues costs probability technical regulatory success expected cash flows included cash flows hrher metastatic breast cancer thirdline plus patients patients earlier lines therapy subject separate clinical studies revised discounted cash flows lower primarily due delay launch timing thirdline plus patients caused decrease market share assumptions based expected competitive environment march changes plans assumptions related estimated cash flows patients earlier lines therapy used discount rate based estimated weightedaverage cost capital companies profiles similar represents rate market participants would use value intangible assets determined revised estimated fair value carrying value asset result recognized partial impairment charge billion inprocess research development impairments consolidated statements income three months ended march financial information accounts receivable net following table summarizes accounts receivable net december millions accounts receivable less allowances chargebacks less allowances cash discounts less allowances credit losses accounts receivable net majority trade accounts receivable arises product sales us europe inventories following table summarizes inventories december millions raw materials work process finished goods total reported inventories longterm assets total amounts primarily consist raw materials current liabilities following table summarizes components current liabilities december millions compensation employee benefits income taxes payable allowance sales returns current liabilities accumulated comprehensive income loss following table summarizes changes accumulated comprehensive income loss component net tax unrealized gains unrealized gains losses available losses cash foreign currency forsale debt flow hedges net millions translation securities net tax tax total balance december net unrealized loss gain reclassifications net income comprehensive loss income net balance december net unrealized loss gain reclassifications net income comprehensive loss net balance december net unrealized gain loss reclassifications net income comprehensive income loss net balance december restructuring incurred restructuring charges totaling million primarily due changes manufacturing strategy included decision longer utilize certain facilities result decision determined related assets fully impaired based difference fair value carrying amount total charges consisted writeoffs manufacturing assets million writeoffs inventory million costs million result recorded million charge cost goods sold million charge research development expenses million charge selling general administrative expenses consolidated statements income debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions carrying amount type borrowing issue date maturity date interest rate december december senior unsecured september september senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october total senior unsecured notes liability related future royalties total debt net less current portion longterm debt obligations net total longterm debt net senior unsecured notes september issued billion aggregate principal amount senior unsecured notes registered offering consisting billion principal amount senior unsecured notes due october billion principal amount senior unsecured notes due october additionally september repaid maturity billion principal balance related senior unsecured notes due september senior unsecured notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined terms notes senior unsecured notes also par call feature exercisable option redeem notes par whole part dates ranging two six months prior maturity case accrued unpaid interest also required redeemed date redemption event change control downgrade rating senior unsecured notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants note indentures governing senior unsecured notes december violation covenants liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi finance trust rpi prior acquisition immunomedics funding agreement rpi right receive certain royalty amounts subject certain reductions based net sales trodelvy calendar quarter term agreement approximately liability amortized using effective interest rate method resulting recognition interest expense years estimated timing amount future expected royalty payments estimated term reassessed reporting period impact changes estimates recognized liability related interest expense prospectively revolving credit facilities june entered billion fiveyear revolving credit facility maturing june revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facility revolving credit facility contains customary representations warranties affirmative negative covenants events default december compliance covenants loans revolving credit facility bear interest either term sofr plus applicable percentage ii base rate plus applicable percentage defined revolving credit facility agreement may terminate reduce commitments may prepay loans credit facility whole part time without premium penalty contractual maturities financing obligations following table summarizes aggregate future principal maturities senior unsecured notes december millions amount thereafter total leases operating leases consist primarily properties equipment administrative manufacturing rd activities leases include options extend terms years include options terminate lease within one year lease commencement date december material finance leases operating lease expense including variable costs shortterm leases million million million years ended december respectively following table summarizes balance sheet information related operating leases december millions except weighted average amounts classification rightofuse assets net longterm assets lease liabilities current current liabilities lease liabilities noncurrent longterm obligations weighted average remaining lease term years years weighted average discount rate following table summarizes supplemental information related operating leases year ended december millions cash paid amounts included measurement lease liabilities rightofuse assets obtained exchange lease liabilities represent noncash activities therefore included consolidated statements cash flows following table summarizes maturity analysis operating lease liabilities showing aggregate lease payments december millions amount thereafter total undiscounted lease payments less imputed interest total discounted lease payments commitments contingencies legal proceedings party various legal actions certain significant matters described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted outcome matters either expected material possible determine reasonably estimate maximum potential exposure range possible loss recorded expense million selling general administrative expenses consolidated statements income settlements certain plaintiffs hiv antitrust litigation paid second half material accruals matters described december december litigation relating preexposure prophylaxis august filed petitions requesting inter partes review us patent nos collectively hhs patents patent trial appeal board ptab hhs patents assigned us department health human services hhs purport claim process protecting primate host infection immunodeficiency retrovirus administering combination ftc tenofovir disoproxil fumarate tdf taf prior exposure host immunodeficiency retrovirus process commonly known preexposure prophylaxis prep november us department justice filed lawsuit us us district court delaware alleging sale truvada descovy use prep infringes hhs patents february ptab declined institute petitions inter partes review hhs patents april filed lawsuit us federal government us court federal claims cfc alleging breach three material transfer agreements mtas related research underlying hhs patents two clinical trial agreements ctas us centers disease control prevention related prep research trial bifurcated portion lawsuit cfc held june november cfc determined government breached mtas january cfc found government liable breach ctas may district court held trial regarding governments patent infringement claims jury rendered full defense verdict favor gilead finding asserted claims hhs patents invalid hhs patents infringed government filed posttrial motions expect district court issue decision motions first quarter although predict certainty ultimate outcome litigation matters believe us federal government breached contracts gilead truvada descovy infringe hhs patents hhs patents invalid prior art descriptions truvadas use prep postexposure prophylaxis physicians patients using claimed methods years hhs filed applications patents separate trial cfc determine damages gilead owed based governments breach yet scheduled litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions products approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products prior patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval october received letter lupin ltd lupin indicating submitted anda fda requesting permission market manufacture generic version symtuza product commercialized janssen gilead shares revenues november along janssen janssen products lp filed patent infringement lawsuit lupin coplaintiffs us district court delaware september received letter apotex inc apotex corp apotex stating submitted anda generic version symtuza october along janssen janssen products lp filed patent infringement lawsuit apotex coplaintiffs us district court delaware cases lupin apotex consolidated single trial scheduled may starting march received letters lupin laurus labs laurus cipla ltd cipla indicating submitted andas fda requesting permission market manufacture generic versions adult dosage strength biktarvy lupin laurus cipla challenged validity four six patents listed orange book associated biktarvy filed lawsuit lupin laurus cipla may us district court delaware intend enforce defend intellectual property trial scheduled october additionally november received letter cipla indicating submitted anda fda requesting permission market manufacture generic version pediatric dosage strength biktarvy cipla challenged validity two patents listed orange book associated biktarvy filed separate lawsuit cipla december us district court delaware june received letter apotex indicating submitted anda fda requesting permission market manufacture generic version genvoya july filed patent infringement lawsuit apotex us district court delaware intend enforce defend intellectual property case consolidated symtuza matters discussed trial scheduled june antitrust consumer protection along bristolmyers squibb company bms johnson johnson inc johnson johnson teva pharmaceutical industries ltd teva named defendants class action lawsuits filed related various drugs used treat hiv including drugs used combination antiretroviral therapy plaintiffs allege defendants engaged various conduct restrain competition violation federal state antitrust laws state consumer protection laws lawsuits consolidated pending us district court northern district california lawsuits seek bring claims behalf direct purchasers consisting largely wholesalers indirect endpayor purchasers including health insurers individual patients plaintiffs seek damages permanent injunctive relief relief second half first half several plaintiffs consisting retail pharmacies individual health plans united healthcare filed separate lawsuits effectively opting class action cases asserting claims substantively classes cases coordinated class actions march district court granted motion hold separate trials allegations us teva seeking monetary damages relating truvada atripla phase ii allegations us part johnson johnson seeking monetary damages injunctive relief relating complera phase ii may settled claims direct purchaser class retailer optout plaintiffs million paid second half settlement agreements admission liability fault us subject number conditions including respect preliminary settlement agreement us direct purchaser class court approval june jury returned complete verdict gileads favor remaining plaintiffs phase allegations november court denied plaintiffs motion set aside verdict plaintiffs indicated intend appeal jury verdict trial phase ii claims yet scheduled plaintiffs phase defendants requested court stay phase ii pending appeal phase intend vigorously defend phase ii claims predict ultimate outcome plaintiffs successful phase ii claims could required pay monetary damages could subject permanent injunctive relief favor plaintiffs january along bms janssen products lp named defendants lawsuit filed superior court state california county san mateo aetna inc behalf affiliates subsidiaries effectively opts aetna plaintiffs class actions allegations substantively class actions aetna plaintiffs seek damages permanent injunctive relief relief september filed motion judgment pleadings preclude aetna relitigating claims dismissed summary judgment class action cases motion remains pending september along generic manufacturers cipla cipla usa inc together cipla defendants named defendants class action lawsuit filed us district court northern district california jacksonville police officers fire fighters health insurance trust jacksonville trust behalf endpayor purchasers jacksonville trust claims settlement agreement us cipla defendants settled patent dispute relating patents covering emtriva truvada atripla products permitted generic entry prior patent expiry violates certain federal state antitrust consumer protection laws plaintiffs sought damages permanent injunctive relief relief january settled plaintiffs claim de minimis fee february along bms teva named defendants lawsuit filed first judicial district court state new mexico county santa fe new mexico attorney general new mexico attorney general alleges defendants restrained competition violation new mexico antitrust consumer protection laws new mexico attorney general seeks damages permanent injunctive relief relief moved dismiss case based lack personal jurisdiction july new mexico supreme court remanded case back trial court limited jurisdictional discovery intend vigorously defend actions however predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages could subject permanent injunctive relief awarded favor plaintiffs may result material adverse effect results operations financial condition including particular reporting period outcome becomes probable estimable product liability named defendant one class action lawsuit various product liability lawsuits related viread truvada atripla complera stribild plaintiffs allege viread truvada atripla complera andor stribild caused experience kidney bone andor tooth injuries lawsuits pending state federal court california missouri involve active plaintiffs plaintiffs cases seek damages relief various grounds alleged personal injury economic loss first bellwether trial california state court scheduled begin october currently stayed pending conclusion appellate proceedings california first district court appeal california supreme court first bellwether trial california federal court scheduled begin november intend vigorously defend actions however predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages may result material adverse effect results operations financial condition including particular reporting period outcome becomes probable estimable government investigation received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry qui tam litigation former sales employee filed qui tam lawsuit gilead march us district court eastern district pennsylvania following governments decision intervene suit case unsealed december lawsuit alleges certain gileads hcv sales marketing activities violated federal false claims act various state false claims acts lawsuit seeks available relief statutes health choice advocates llc health choice filed qui tam lawsuit gilead april new jersey state court following new jersey attorney generals offices decision intervene suit health choice served us original complaint august lawsuit alleges gilead violated new jersey false claims act clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief new jersey false claims act april trial court granted motion dismiss prejudice health choice appealed trial courts dismissal health choice filed another qui tam lawsuit gilead may making similar allegations texas state court lawsuit alleged gilead violated texas medicare fraud prevention act tmfpa clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit sought available relief tmfpa health choice voluntarily dismissed case without prejudice august commenced new action october asserting largely identical allegations claims newly filed action texas attorney general intervened plaintiff intend vigorously defend actions however predict ultimate outcomes plaintiffs successful claims could required pay significant monetary damages may result material adverse effect results operations financial condition including particular reporting period outcome becomes probable estimable matters party various legal actions arose ordinary course business believe probable reasonably possible legal actions material adverse impact consolidated financial position results operations cash flows employee benefits stockbased compensation equity incentive plans summary may stockholders approved adopted gilead sciences inc equity incentive plan amended plan part forty seven inc acquisition assumed forty seven inc equity incentive plan subsequently amended restated gilead sciences inc equity incentive plan amended restated plan part immunomedics acquisition assumed immunomedics amended restated longterm incentive plan subsequently merged plan may stockholders approved adopted gilead sciences inc equity incentive plan plan plan authorized issuance total million shares common stock awards may granted plan plan since approval plan broadbased incentive plans provide grant equitybased awards including rsus psus stock options restricted stock performance awards employees directors consultants december total million shares remain available future grant plan rsus grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus sharebased awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant rsus dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit psus grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved psus dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit stock options option grants designated either nonstatutory incentive stock options exercise price stock options may less fair market value common stock grant date stock option may term excess years employee stock options generally vest three four years stock options may settled cash shares common stock including net issuance using shares otherwise purchasable option pay exercise price espp summary espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers sixmonth look back feature espp purchases settled common stock espps previously authorized available pool shares total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation expense following tables summarize total stockbased compensation expense included consolidated statements income classified award type expense type year ended december millions rsus psus stock options espp acquisitionrelated expense stockbased compensation expense included total costs expenses accelerated postacquisition stockbased compensation expenses million million related xinthera tmunity acquisitions respectively million related mirobio acquisition year ended december millions cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax rsus following tables summarize rsu activity rsus weighted average grant date fair millions except per share amounts shares value per share outstanding december granted vested forfeited outstanding december year ended december millions except per share amounts weightedaverage grant date fair value rsus granted total fair value rsus respective vesting dates december billion unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years psus following tables summarize psu activity psus weighted average grant date fair millions except per share amounts shares value per share outstanding december granted vested forfeited outstanding december year ended december millions except per share amounts weightedaverage grant date fair value psus granted total fair value psus respective vesting dates december million unrecognized compensation cost related unvested psus expected recognized weightedaverage period years stock options following tables summarize activity information related stock options weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value millions dollars years millions outstanding december granted exercised forfeited expired outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable year ended december millions except per share amounts weightedaverage grant date fair value stock options granted total intrinsic value options exercised used following weightedaverage assumptions blackscholes model calculate estimated fair value stock option awards year ended december expected volatility expected terms years riskfree interest rate expected dividend yield december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years espp following table summarizes espp activity year ended december millions except per share amounts shares issued amount paid employees shares weightedaverage grant date fair value espp shares granted total fair value espp shares respective vesting dates used following weightedaverage assumptions blackscholes model calculate estimated fair value espp awards year ended december expected volatility expected terms years riskfree interest rate expected dividend yield deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million years ended december respectively maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan approximately million million december respectively earnings per share following table shows calculation basic diluted earnings per share attributable gilead year ended december millions except per share amounts net income attributable gilead shares used basic earnings per share attributable gilead calculation dilutive effect stock options equivalents shares used diluted earnings per share attributable gilead calculation basic earnings per share attributable gilead diluted earnings per share attributable gilead potential shares common stock excluded computation diluted earnings per share attributable gilead effect would antidilutive million million million years ended december respectively income taxes income income taxes consists following year ended december millions domestic foreign income income taxes income tax expense consists following year ended december millions federal current deferred state current deferred foreign current deferred income tax expense reconciliation federal statutory tax rate applied income income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings foreignderived intangible income deduction tax examinations acquired iprd related charges changes valuation allowance nontaxable unrealized loss investment effective tax rate significant components deferred tax assets liabilities follows december millions deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible excess tax basis book basis intangible assets upfront milestone payments research credit carryforwards equity investments liability related future royalties capitalized rd expenditures net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities property plant equipment excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax assets liabilities valuation allowance increased million million years ended december december respectively primarily due unrealized losses equity investments subject full valuation allowance december us federal net operating loss tax credit carryforwards approximately million million respectively start expire respectively utilized addition state net operating loss tax credit carryforwards approximately billion billion respectively start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns us many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service tax years differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition interest penalties related unrecognized tax benefits included income tax benefit million income tax benefit million income tax expense million consolidated statements income years ended december respectively accrued interest penalties related unrecognized tax benefits million million december respectively believe reasonably possible unrecognized tax benefits may decrease approximately million next months due potential resolutions tax authority following rollforward total gross unrecognized tax benefits year ended december millions beginning balance tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations ending balance connection tax cuts jobs act recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period federal income tax payable transition tax billion billion december respectively following table summarizes anticipated timing payments associated transition tax december millions amount total subsequent events evaluated subsequent events determined addition already disclosed elsewhere notes consolidated financial statements included annual report following events transactions met definition subsequent event purposes recognition disclosure dividend february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors item changes disagreements accountants accounting financial disclosure applicable report independent registered public accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san mateo california february item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae de securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af df exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting quarter ended december identify change materially affected reasonably likely materially affect internal control financial reporting august began deploying new enterprise resource planning system erp well related systems made changes internal control financial reporting address related processes systems continue evaluate changes internal control financial reporting course implementation new erp related systems scheduled occur phases next years item b information november merdad v parsey md phd chief medical officer adopted trading plan intended satisfy rule bc exchange act sell subject certain conditions november shares common stock b total number shares common stock sufficient cover costs fees satisfy applicable withholding taxes connection exercise stock options c net shares common stock issued dr parsey satisfaction applicable withholding taxes following potential vesting settlement performance shares item c disclosure regarding foreign jurisdictions prevent inspections applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers applicable delinquent section reports written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website wwwgileadcom investors section governance governance documents intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation talent committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading securities authorized issuance equity compensation plans section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item